Pathophysiologic Implications of Membrane Phospholipid Asymmetry in Blood Cells

Blood online

SEARCH:

Advanced

This Article

Full Text (PDF)

Alert me when this article is cited

Alert me if a correction is posted

Citation Map

Services

Email this article to a friend

Similar articles in this journal

Similar articles in PubMed

Alert me to new issues of the journal

Download to citation manager

Rights and Permissions

Citing Articles

Citing Articles via HighWire

Citing Articles via CrossRef

Citing Articles via Google Scholar

Google Scholar

Articles by Zwaal, R. F.A.

Articles by Schroit, A. J.

Search for Related Content

PubMed

PubMed Citation

Articles by Zwaal, R. F.A.

Articles by Schroit, A. J.

Related Collections

Review Articles

Social Bookmarking


What's this?

Next Article

Blood, Vol. 89 No. 4 (February 15), 1997: pp. 1121-1132

REVIEW ARTICLE

Pathophysiologic Implications of Membrane Phospholipid Asymmetry in Blood Cells

By Robert F.A. Zwaal and Alan J. Schroit
From the Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands; and The University of Texas M.D. Anderson Cancer Center, Houston, TX.

  INTRODUCTION

Introduction
References

MANY STUDIES HAVE led to the concept that membrane phospholipid asymmetry is ubiquitous. In general terms, the outer leaflet of eukaryotic plasma membranes is formed predominantly with the cholinephospholipids (sphingomyelin and phosphatidylcholine [PC]), whereas the majority of the aminophospholipids (phosphatidylserine [PS] and phosphatidylethanolamine [PE]) are confined to the membrane's inner leaflet. This selective localization dictates that asymmetric biomembranes are assembled and maintained by specific mechanisms that control transbilayer lipid sidedness. In 1984, it became clear that asymmetry was generated by the activity of an adenosine triphosphate (ATP)-dependent aminophospholipid translocase that specifically transports PS and PE between bilayer leaflets.¹ This discovery underscored the prevailing concept that membrane lipid asymmetry was of major physiologic importance, because it showed that cells invest energy to catalyze lipid movement in order to maintain a specific transmembrane phospholipid distribution.

Although asymmetry is the rule for normal cells, loss of asymmetry, especially the appearance of PS at the cell surface, is associated with many physiologic and pathologic phenomena. Bevers et al²^,³ were the first to report that the asymmetric orientation of phospholipids in blood platelets was rapidly lost upon influx of calcium during their activation, a finding that suggested a critical role for PS in thrombosis.⁴^,⁵ Apoptotic^6-9 and tumorigenic cells¹⁰^,¹¹ also express relatively large amounts of outer-leaflet PS that may serve as a trigger for macrophage recognition and promote the cells' phagocytosis.^12-15

In this essay, we summarize recent observations on the perturbation of membrane phospholipid asymmetry and present a somewhat stochastic view of the patho-physiologic implications of surface-exposed PS. We also review briefly the mechanisms believed to be responsible for the regulation of phospholipid distributions across plasma membranes. Other details of transbilayer lipid distributions and the various techniques used in this field will not be discussed; several recent reviews of these and related topics have been published elsewhere.^16-21

  REGULATION OF MEMBRANE PHOSPHOLIPID TOPOGRAPHY

At least three distinct activities are involved in the regulation of membrane lipid sidedness. Two energy-requiring activities seem to work in concert to maintain a nonrandom transbilayer phospholipid orientation. Inhibition of these activities stops lipid movement, but it does not result in loss of asymmetry for at least several days in vitro. Influx of Ca²⁺ into the cytoplasm, on the other hand, activates a scramblase activity that results in rapid transbilayer phospholipid mixing that leads to a nearly symmetric distribution of phospholipids across the membrane bilayer (Fig 1).

View larger version (74K):
[in this window]
[in a new window]
Fig 1. The regulation and physiology of membrane phospholipid asymmetry. This model describes how membrane phospholipid asymmetry is generated, maintained, and perturbed as a prerequisite to various phosphatidylserine-related pathophysiologies. Membrane lipid asymmetry is regulated by the cooperative activities of three transporters. The ATP-dependent aminophospholipid-specific translocase, which rapidly transports PS and PE from the cell's outer-to-inner leaflet; the ATP-dependent nonspecific lipid floppase, which slowly transports lipids from the cell's inner-to-outer leaflet; and the Ca²⁺-dependent nonspecific lipid scramblase, which allows lipids to move randomly between both leaflets. The model predicts that the translocases are targets for Ca²⁺ that directly regulates the transporter's activities. The figure shows that elevated intracellular Ca²⁺ induces PS randomization across the cell's plasma membrane by providing a stimulus that positively and negatively regulates scramblase and translocase activities, respectively. At physiologic Ca²⁺ concentrations, PS asymmetry is promoted because of an active translocase and floppase but inactive scramblase. Depending on the type of cell, elevated intracellular Ca²⁺ levels can be achieved by cellular activation that generally results in the concomitant influx and accumulation of extracellular Ca²⁺ and by its release from intracellular stores. Increased cytosolic Ca²⁺ can also result in calpain activation, which facilitates membrane blebbing and the release of PS-expressing procoagulant microvesicles. Exposure of PS at the cell's outer leaflet. The appearance of PS at the cell's outer leaflet promotes coagulation and thrombosis by providing a catalytic surface for the assembly of the prothrombinase and tenase (not shown) complexes and marks the cell as a pathologic target for elimination by phagocytes. Recognition of the PS-expressing targets can occur by both antibody-dependent and direct receptor-mediated pathways. (Aminophospholipids are shown with red polar headgroups and cholinephospholipids with blue polar headgroups, see cover photo; $beta$ 2-Gp, $beta$ 2-glycoprotein-I; rec, receptor).

Aminophospholipid translocase. The discovery of an ATP-dependent aminophospholipid translocase in red blood cells has provided direct evidence for the existence of mechanisms that generate and maintain membrane asymmetry through the transport of specific lipids across the cell's membrane.¹^,²²^,²³ This activity is distinguished by its ability to transport PS and PE from the outer to inner leaflet of plasma membranes against the concentration gradient. Cholinephospholipids are not moved. Competition experiments have shown that the same protein transports both PS and PE, although PS is transported much faster, with half-times of 5 to 10 minutes.²⁴^,²⁵ This process consumes one molecule of ATP per molecule of lipid transported.²⁶ Transport is stereospecific for naturally occurring L-isomers of the glycero-backbone²⁷ and is inhibited by vanadate,¹ sulfhydryl-reactive reagents,²⁸^,²⁹ and the histidine-reactive reagent bromophenacylbromide.²⁵ In addition, activity is abrogated when cytoplasmic Ca²⁺ levels reach micromolar concentrations.³⁰^,³¹

Although these observations clearly indicate that lipid transport is catalyzed by one or more membrane proteins, its identity is still uncertain. A 110-kD Mg²⁺-ATPase has been partially purified^32-34 and reconstituted into artificial lipid vesicles with at least a fraction of its active center at the outer face.³⁵ These vesicles transported a spin-labeled PS analog from the inner to outer leaflet upon the addition of Mg²⁺-ATP, suggesting that this ATPase is responsible for aminophospholipid translocation. However, it was recently reported that, similar to previous purification strategies,³³ the active fraction was not homogenous and contained several proteins ranging from 35 kD to 120 kD.³⁶ These observations preclude assignment of the transporter to a single protein and are not inconsistent with studies implicating the involvement of a 30-kD to 32-kD band 7 transmembrane polypeptide in aminophospholipid transport.²⁸^,³⁷^,³⁸ This protein, which may be complexed to Rh polypeptides, was preferentially labeled in erythrocyte membranes with a photoactivatable PS analog only under conditions conducive to PS transport.²⁵^,³⁹^,⁴⁰ Consistent with these observations, aminophospholipid transport activity was suggested to require the coordinated and complimentary participation of a Mg²⁺-ATPase and a 32-kD protein,¹⁶ a motif not uncommon for the ATP-binding cassette (ABC) family of proteins to which the aminophospholipid translocase might belong.⁴¹^,⁴²

Aminophospholipid translocase activity has been observed in other membranes, including intracellular chromaffin granule membranes⁴³ and endoplasmatic reticulum.⁴⁴ Activity has also been shown in various cells,³¹^,^45-50 including endothelial cells, in which its expression is regulated by basic fibroblast growth factor.⁵¹ Mutants defective in PS transport have been isolated.⁵²

ATP-dependent floppase. Another ATP-dependent translocating activity has been described that, in conjunction with the aminophospholipid translocase, may regulate the differential transbilayer orientation of phospholipids in complex biologic membranes. A less specific ATP-requiring floppase, first discovered in red blood cells, transports both aminophospholipids and cholinephospholipids from the inner to the outer leaflet with half-times about 10 times longer than those of the translocase-mediated inward movement of PS and PE.²⁵^,^53-55 Similar to inward transport of aminophospholipids, outward movement was found to be abrogated by ATP depletion, sulfhydryl oxidation, and histidine modification, indicating that this process is also energy- and protein-dependent.²⁵ Whether outward transport is an intrinsic property of the aminophospholipid translocase or is caused by the activity of a distinct membrane protein or protein complex is not known. Because rapid inward translocation of aminophospholipids does not accelerate outward migration of all phospholipids, both processes may be mediated by independent mechanisms.²⁵ Nonetheless, both lipid-transporting activities seem to act in concert and establish a dynamic asymmetric steady-state in which all phospholipids are slowly but continuously moved to the outer membrane surface, whereas the aminophospholipids are shuttled directly back to the inner leaflet.²¹^,²⁵ Thus, the combined action of translocase and floppase seems to equip the cell with a mechanism that corrects for alterations in lipid distributions to avoid potential pathologic consequences. Whereas the maintenance of membrane lipid is asymmetry is stable and resistant to the mechanical stresses⁵⁶ likely endured in the peripheral circulation, rapid perturbations in lipid asymmetry could be coincident to different membrane fusion events that accompany endocytosis and exocytosis.¹⁷^,³¹^,^57-60

Lipid scramblase. Platelet plasma membranes harbor a Ca²⁺-dependent mechanism that can rapidly move phospholipids back and forth between the two membrane leaflets (flip-flop), leading within minutes to a loss of membrane lipid asymmetry.²^,³ Because the influx of Ca²⁺ also abrogates aminophospholipid translocase activity,³⁰^,³¹^,⁴⁶ Ca²⁺-dependent loss of membrane phospholipid asymmetry is not corrected. Considering that spontaneous transbilayer migration of lipids is thermodynamically unfavorable, Ca²⁺-induced lipid randomization is likely to depend on a protein or proteins with lipid scramblase activity.⁶¹ Indeed, the existence of an inherited bleeding disorder (Scott syndrome, see below), characterized by an impairment of scramblase activity, reinforces the notion that specific membrane proteins are involved in this process.^62-64 Ca²⁺-induced scramblase activity has also been found in other cells, but its activity is usually lower than in blood platelets (reviewed previously¹⁶^,¹⁸ ).

Scramblase activity requires the continuous presence of cytoplasmic calcium.⁶⁵ Provided the aminophospholipid translocase is not irreversibly inactivated by intracellular calpain, Ca²⁺ efflux can lead to restoration of lipid asymmetry.⁵⁷ Lipid scrambling is bidirectional, and all major lipid classes move back and forth at comparable rates.⁴⁶^,⁶⁵^,⁶⁶ Unlike the energy-dependent translocase and floppase, the lipid scramblase does not require hydrolyzable ATP. However, its activity partially decreases during prolonged ATP depletion.⁶⁷^,⁶⁸ Proteins fractionated from platelet membranes have been reconstituted into artificial lipid vesicles, which exhibited Ca²⁺-dependent lipid-scrambling activity that was pronase-, heat-, and sulfhydryl-sensitive.⁶⁹ Similar experiments performed with proteins from red blood cell membranes suggested that a 37-kD protein may be responsible for lipid scrambling activity.⁷⁰ Although these data indicate that a protein is responsible for scramblase activity, it has also been proposed that lipid scrambling is the result of a complex between phosphatidylinositol 4,5-bisphosphate and calcium.⁶⁷ In addition to the protein reconstitution studies, other experiments also indicate that such a mechanism cannot account for the scramblase activity observed in platelets.⁷¹

Loss of membrane lipid asymmetry is often accompanied by blebbing and subsequent shedding of lipid-symmetric microvesicles from the cell surface.⁵⁷^,^72-75 Fusion between opposing segments of plasma membrane before the release of microvesicles was proposed to cause a localized collapse of lipid asymmetry.⁷² However, recent evidence indicates that this is not the mechanism responsible for lipid scrambling because (1) Ca²⁺-induced randomization of lipids can occur in the absence of microvesicle formation under conditions in which activation of intracellular calpain is prevented^75-77 and (2) lipid scrambling and microvesicle formation are deficient in Scott syndrome⁷² but calpain activity is normal.⁶² Thus, at least both lipid scrambling and calpain activation are required for shedding of microvesicles (Fig 1).

In summary, the synchronous and cooperative action of the aminophospholipid translocase and the nonspecific floppase contribute to the generation and maintenance of membrane phospholipid asymmetry, whereas lipid scramblase activity results in its collapse. At physiologic (ie, low) cytoplasmic Ca²⁺ levels, both aminophospholipid translocase and nonspecific floppase are active, and phospholipid asymmetry is maintained. Conversely, high cytoplasmic Ca²⁺ concentrations activate lipid scramblase and block the cooperative action of translocase and floppase, leading to randomization of phospholipids across the membrane lipid bilayer. Conceivably, intermediate Ca²⁺ levels could lead to a circumstance in which both mechanisms are active and oppose each other.²¹ These situations can accommodate a wide range of steady-state distributions of membrane phospholipids commonly seen in in vitro stored red blood cells,^78-80 sickle cells,^81-84 blood cells from diabetics,⁸⁵^,⁸⁶ aged red blood cells,⁸⁷^,⁸⁸ and undifferentiated tumorigenic cells.¹⁰^,¹¹

Other mechanisms. Many studies have suggested that cytoskeletal proteins assist in the maintenance of membrane phospholipid asymmetry by selectively interacting with aminophospholipids.^89-91 However, the interaction between PS and cytoskeletal proteins is thermodynamically weak and there is evidence that lipid asymmetry can be generated and maintained in artificial membrane preparations that lack cytoskeletal proteins.²⁶^,⁹²^,⁹³ Moreover, spherocytic erythrocytes fully conserve lipid asymmetry despite markedly diminished levels of spectrin.⁹⁴ Although these observations do not unequivocally rule out the cytoskeleton's function in the maintenance of lipid asymmetry, it is presumably not of major importance.

Another group of proteins that translocate lipid or lipid-soluble compounds across the plasma membrane have recently received wide attention. Unidirectional transport of PC is catalyzed by a member of the P-glycoprotein family in the canalicular domain of murine hepatocyte plasma membranes to provide PC for bile production.⁹⁵^,⁹⁶ This membrane glycoprotein is encoded by the murine multidrug resistance gene mdr2 and belongs to the family of ABC proteins. Although its behavior resembles that of the ATP-dependent translocase and floppase, its lipid specificity is clearly different. Moreover, its presence may be restricted to hepatocyte membranes, precluding a role in establishing lipid asymmetry in other cells. However, P-glycoprotein encoded by the mdr1 gene is abundantly expressed in drug-resistant tumor cells, where it nonselectively expels lipid-soluble compounds from the inner to the outer membrane leaflet.⁹⁷^,⁹⁸ Although the properties of the mdr1 P-glycoprotein resemble those of the nonselective red blood cell floppase, their possible relationship remains to be explored.

A recent proposal is that, unlike phospholipid scrambling in red blood cells, PS exposure in activated platelets is caused by a vectorial inward-outward aminophospholipid-specific transport mechanism.⁹⁹^,¹⁰⁰ This conclusion contrasts with observations from other laboratories that show Ca²⁺-induced lipid scrambling involves nonspecific flip-flop of all lipid classes.³^,⁴⁶^,⁶⁵^,⁶⁶^,⁷²^,¹⁰¹ Platelets are unlikely to have a specific mechanism different from that of red blood cells because the hereditary abnormality in PS exposure in Scott syndrome equally affects both platelets and erythrocytes.¹⁰² Moreover, insurmountable shape changes would be produced by the large mass-imbalance generated when outward transport of aminophospholipids is not compensated by inward transport of other lipids.¹⁸ Indeed, less than 1% of a mass imbalance produces large shape changes in giant unilamellar liposomes.¹⁰³ Although the cell might be able to compensate for bilayer imbalances by releasing microvesicles, PS exposure in platelets can occur without microvesicle release.⁷⁷

  HEMOSTASIS AND THROMBOSIS

Lipids and coagulation. Membrane phospholipids propagate the proteolytic reactions that result in thrombin formation by promoting the assembly of coagulation factors on their surface. The most important pathway of coagulation is initiated by tissue factor, an integral membrane protein expressed on the surface of activated or disrupted cells.^104-107 Tissue factor interacts with factor VII or VIIa, and this complex rapidly converts the zymogen factor IX, factor X, and factor VII itself into their active forms. Although assembly and catalytic activity of the tissue factor/factor VIIa complex is effective in the absence of anionic phospholipids, activity is increased by PS.^108-110 However, anionic phospholipids are indispensable in promoting membrane binding and catalytic activity of the two subsequent coagulation factor complexes in the cascade that leads to thrombin formation.¹⁰⁶^,¹¹¹ The tenase complex is initiated by the interaction of factor VIIIa with negatively charged lipid to create a high-affinity binding site for the enzyme factor IXa in the presence of Ca²⁺. This complex rapidly activates factor X into Xa. Likewise, in the prothrombinase complex, binding of factor Va to an anionic lipid surface promotes Ca²⁺-dependent binding of factor Xa, which converts prothrombin to thrombin (Fig 1). In both complexes, PS is the most effective anionic phospholipid.¹¹² Binding of factors Va and VIIIa to naturally occurring phosphatidyl-L-serine is stereospecific and occurs with lower affinity to phosphatidyl-D-serine and other anionic phospholipids.¹¹³^,¹¹⁴ PS is equally important in promoting the anticoagulant protein C pathway that provides feedback inhibition of thrombin formation. Protein C effectively inactivates factor Va when both are bound to the same lipid surface, which leads to disassembly of the prothrombinase complex.¹⁰⁵^,¹¹⁵

Procoagulant activity of blood platelets. Surface exposure of PS in platelet membranes provides for efficient propagation and control of the hemostatic process. Kalafatis et al¹⁰⁶ have argued that specific protein receptors for factors Va and VIIIa may, in addition to PS binding sites, be present in cellular membranes. However, it should be noted that phospholipases¹¹⁶ and annexin V¹¹⁷ inhibit platelet prothrombinase activity. Although this does not eliminate the putative existence of protein receptors, these data prove that PS exposure is critical to coagulation. However, because platelets do not contain tissue factor they cannot initiate the coagulation cascade. Moreover, annexin V inhibits prothrombin activation only in cells that express both tissue factor- and prothrombinase-binding sites.¹¹⁸ These data indicate that surface exposure of PS is required for propagation but not necessarily for initiation of the coagulation process.

The extent to which membrane phospholipid asymmetry becomes perturbed during platelet activation correlates with the cells' ability to promote tenase and prothrombinase activity¹¹⁹ and depends on the type of agonist.³^,⁷²^,¹²⁰^,¹²¹ Ca²⁺-ionophore is the most effective followed by complement membrane attack complex C5b-9, collagen + thrombin, collagen, and thrombin. ADP and epinephrine have no effect. The same order of agonist activity is observed for the extent of lipid-symmetric microvesicle shedding from the platelet surface.⁷²^,⁷⁵

Platelet activation after vascular damage involves adhesion to subendothelial structures and aggregation of platelets to form a primary hemostatic plug at the wound site. The exposure of PS on aggregated platelets restricts and controls thrombin formation at the site of injury by providing a catalytic membrane surface for both procoagulant (tenase and prothrombinase) and anticoagulant (protein C) reactions. The physiologic significance of platelet-derived microvesicles is not clear. Because microvesicles tend to circulate rather than stick to the platelet aggregate, it is thought that they may be associated with thrombotic conditions. Indeed, increased amounts of circulating microvesicles have been observed in patients suffering from various disorders associated with secondary activated coagulation¹²² and in patients with such primary thrombotic disorders as transient ischemic attacks and myocardial infarction.¹²³^,¹²⁴ It has also been shown that platelet microvesicles bind to and activate neutrophils, suggesting that hemostasis and inflammation may be linked.¹²⁵ Indeed, it has recently been shown that the leukocyte adhesion molecule L-selectin binds PS.¹²⁶ Thus, activation and aggregation of platelets at the site of injury could recruit leukocytes to the site of inflammation via the binding of platelet-exposed PS to leukocyte L-selectin. Unlike platelet-derived microvesicles, microparticles released from other cells may also contain tissue factor activity and initiate undesired coagulation in the circulation.¹¹⁸^,¹²⁷^,¹²⁸

Scott syndrome, a disorder of Ca-induced lipid scrambling. Scott syndrome, which was first described by Weiss et al,¹²⁹ is a rare, moderately severe, bleeding disorder characterized by a deficiency in platelet procoagulant activity that is not associated with decreased coagulation factor levels.⁶³ Although activation of these platelets results in normal secretion and aggregation, they express a relatively low number of factor Va and VIIIa binding sites.¹³⁰^,¹³¹ These cells exhibit decreased surface exposure of PS, reduced ability to promote both tenase and prothombinase activity in response to agonists,⁶² and impaired capacity to shed membrane-derived microvesicles.⁷² Studies of a recently discovered family in France indicated that Scott syndrome is an inherited bleeding disorder transmitted as an autosomal recessive trait.⁶⁴ Remarkably, the defect in Ca²⁺-induced lipid scrambling is not restricted to platelets but can also be shown in the patients' erythrocytes, erythrocyte ghosts,¹⁰² and in Epstein-Barr virus-transformed B-lymphocytes.⁶⁴^,¹³² Experiments with single-cell clones of transformed lymphocytes have suggested that the reduced exposure of PS affects all cells to the same extent. Fusion of the lymphoblasts with a myeloma cell line restored PS exposures to normal levels.¹³² Platelets and erythrocytes from patients with Scott syndrome have normal phospholipid composition and show no obvious protein abnormality when examined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.¹⁰² Taken together, these studies support the notion that Scott syndrome results from a deletion or mutation in multiple hematologic lineages that either affects the putative phospholipid scramblase directly or alters the Ca²⁺-induced activation mechanism.

Procoagulant activity of red blood cells. Although red blood cells lose phospholipid asymmetry and stimulate prothrombinase activity after the addition of Ca²⁺-ionophore,⁵⁴^,⁵⁷^,⁶⁶^,⁶⁸^,¹³³ they are not considered significant in hemostasis and thrombosis. However, the possibility that perturbations in PS exposure contribute to thrombotic events commonly seen in diabetes mellitus and sickle cell crisis should not be dismissed. Indeed, increased procoagulant activity associated with loss of lipid asymmetry has been observed in erythrocytes incubated in hyperglycemic buffers,⁸⁶ in platelets from diabetic patients,¹³⁴ and in vesicles shed from reversibly sickled cells by repeated hypoxia-induced sickling.⁹¹ Interestingly, Ca²⁺-induced transbilayer movement of PS and the generation of red blood cell procoagulant activity is strongly inhibited by high-density lipoprotein (HDL) and apolipoprotein A-1¹³⁵; this raises the possibility that the protective effect of HDL against arterial thrombosis may be due, in part, to HDL-dependent inhibition of thrombogenic surface expression.

Procoagulant activity of white blood cells. Although lipid sidedness has not been investigated in white blood cells, functional assembly of the prothrombinase complex on monocytes, neutrophils, and lymphocytes has been found to be kinetically equivalent to artificial PS-PC vesicles.¹³⁶^,¹³⁷ The prothrombinase activity of monocytes is enhanced by endotoxin activation, a result that supports the notion that their ability to contribute to thrombin formation is important in the thrombotic events associated with inflammation and healing.¹³⁸^,¹³⁹ Interestingly, the prothrombinase activity of activated monocytes can be enhanced by a reduction in their ATP levels and reduced by inhibition of protein synthesis. These observation may be directly related to the appearance of PS at the cell surface. Hypothetically, reduction of ATP would result in inhibiting the aminophospholipid translocase and prevent recovery from the cell's procoagulant state. Conversely, inhibition of protein synthesis would limit expression of the lipid scramblase and prevent PS exposure. Because stimulated monocytes also release microvesicles that express tissue factor activity,^138-141 they have the capacity both to initiate and propagate coagulation in response to an inflammatory stimulus.

Complement activation of endothelial cells. Consistent with the principal anticoagulant function of endothelial cells, prothombinase assembly, even when stimulated with Ca²⁺-ionophore, is poorly supported on these cells.¹⁴² However, an interesting exception is observed upon insertion of complement membrane attack complex C5b-9. In this case, the assembled complement pore is removed from the cell by shedding into procoagulant microvesicles. The remnant cell, having discarded most of the complex, remains mainly noncoagulant.¹⁴² A similar mechanism of complement-mediated formation of procoagulant microvesicles occurs in platelets.¹²¹ This raises the possibility that complement-induced release of microvesicles into the circulation could contribute to inflammation-associated disseminated intravascular coagulation.

Complement-induced loss of lipid asymmetry in cell-derived microvesicles may be an intrinsic property of complement pore formation because incubation of lipid vesicles with C5b-9 causes transbilayer lipid exchange between both leaflets.¹⁴³ Such pore-forming peptides as mellitin have also been shown to promote fast flip-flop of lipids in liposomes.¹⁴⁴ These findings raise the possibility that the mechanism of Ca²⁺-induced phospholipid scrambling in plasma membranes requires the assembly of pore-forming membrane proteins. This model (Fig 1) envisions pore-mediated flip-flop of phospholipids to involve movement of polar headgroups through a central aqueous channel while the fatty acid moieties diffuse along a hydrophobic interface between subunits.¹⁴⁴^,¹⁴⁵ Such a bidirectional transport mechanism implies that the size of the lipid headgroup, rather than its chemical composition, determines which molecules take part in this process and accounts for its lack of specificity.

Neoplasia and thrombosis. Laboratory evidence of hypercoagulability found in cancer patients is likely to be responsible for the symptomatic thromboembolic episodes frequently observed in these patients. The principal problematic features of blast cells are increased expression of tissue factor activity^146-148 and the presence of a tumor-specific cysteine protease^149-151 that directly activates factor X independent of the tissue factor pathway. In addition, different tumorigenic cells also express a catalytic surface that promotes the assembly and catalysis of the prothrombinase complex.¹⁰^,¹¹^,¹¹⁸^,¹⁵² Unlike tissue factor activity, the prothrombinase activity of tumorigenic cells is inhibited by annexin V^118,153 because of competition for PS expressed at the cell surface. Tumor cells also release microvesicles that catalyze prothrombinase activity,¹⁵²^,¹⁵⁴ a process similar to phospholipid scrambling and microvesicle release in other cells. The expression of both tissue factor and PS in the tumor cells and in their shed microvesicles¹²⁸ could facilitate platelet-independent initiation and propagation of coagulation, and it may be responsible for fibrin deposits often seen in solid tumors.

Antiphospholipid syndome and thrombosis. Autoantibodies to phospholipid-binding proteins, which include lupus anticoagulants, comprise a heterogeneous group of circulating Igs that are associated with increased risk of arterial and venous thrombosis, thrombocytopenia, and recurrent abortions.¹⁵⁵^,¹⁵⁶ Although these antibodies were first believed to recognize anionic phospholipids directly, recent evidence indicates that the antibodies are directed against various plasma proteins, particularly when these proteins are bound to anionic phospholipid surfaces.^157-162 These include antibodies to lipid-bound $beta$ 2-glycoprotein-I, prothrombin, protein C, and protein S. Interaction occurs whether the protein antigens are bound to model membranes, activated platelets, or platelet-derived microvesicles.¹⁶³ Some patients have antibodies against only one of the phospholipid-binding proteins, whereas others display a variety of antigenic specificities. The relationship of these antibodies to thrombosis is not clear, especially when one considers that many antibody-positive individuals are asymptomatic. Whereas the presence of antibodies to $beta$ 2-glycoprotein-I seems to be frequently associated with thrombosis, this relationship is less evident for antibodies against prothrombin, protein C, and protein S.¹⁶² This is rather unexpected considering the high thrombotic tendency of patients with hereditary protein C deficiency.

The mechanisms that elicit production of antibodies to lipid-bound serum proteins is unclear. Rather than an aberrant autoimmune response, the production of these antibodies may be a normal response against an antigenic epitope formed by interaction of the plasma proteins with a PS-expressing thrombogenic surface.⁹^,¹⁵⁹ Whatever the mechanism, antibodies against lipid-bound $beta$ 2-glycoprotein-I or prothrombin usually prolong clotting times in vitro by preventing the assembly of prothrombinase or by inhibiting the proteolysis of prothrombin.^157-159^,¹⁶¹ It should be stressed that such a response does not necessarily lead to a bleeding tendency but may only reduce the propensity for thrombosis. Indeed, whereas thrombotic events are frequently observed in cancer, cancer patients who have lupus anticoagulant antibodies have been reported not to suffer from thromboembolic complications.¹⁶⁴

  ROLE OF PS IN CELL-CELL RECOGNITION

Recognition of PS by macrophages. Another feature of PS-expressing cells is their propensity to be recognized by the reticuloendothelial system.¹⁶⁵^,¹⁶⁶ This was first shown by insertion of controlled amounts of fluorescent PS analogs into mouse red blood cells. Reinjection of these cells into syngeneic animals resulted in their rapid removal from the peripheral circulation and accumulation in splenic macrophages and Kupffer cells.¹³ Cell clearance depended on the amount of exogenously-inserted PS, and it occurred when the cells contained only about ~1 mol% of the PS analog. However, clearance was incomplete. This was likely the result of aminophospholipid translocase activity, which continuously pumped PS to the inner leaflet of the circulating cells, thereby eliminating the putative PS ligand and preventing its recognition by macrophages. Anionic lipid-dependent binding to macrophages has also been observed with PS-containing liposomes in vivo¹⁶⁷ and in vitro.¹⁶⁸^,¹⁶⁹ These results underscore the potential significance of PS in cell-cell recognition and have led to the notion that specific receptor ligand interactions mediate the elimination of PS-expressing cells.

Recognition of PS-expressing cells. Normal cells do not expose significant amounts of PS, but pathologic cells seem to have undergone lipid rearrangements that result in PS exposure. Reorientation of PS has been observed, for example, in sickle cell disease⁷⁹^,⁸¹^,⁸³^,⁸⁴^,⁹¹^,¹²⁰^,¹⁷⁰ and $beta$ -thalassemia,¹⁷¹ possibly because of decreased aminophospholipid translocase activity¹⁷² and alterations in passive diffusion rates of lipids between membrane leaflets,¹⁷³ respectively. Apart from the thrombogenic state associated with these diseases, PS exposure might also explain the cells' increased susceptibility to phagocytosis. Indeed, macrophages bind PS-expressing deoxygenated sickle cells¹⁷⁴ and leukemic cells¹⁰ by a mechanism that is PS-dependent. Recovery to a normal, non-PS-expressing, phenotype by reoxygenation of sickle cells¹⁷⁴ or chemically induced differentiation of leukemic cells results in the disappearance of cell surface PS and reduction in macrophage binding.¹⁰^,¹⁷⁵

Normal red blood cells seem to have an intrinsic property whereby they accumulate small amounts of surface-exposed PS over their lifespan.⁷⁹^,⁸⁷^,⁸⁸ Given that macrophages are able to recognize PS, exposure of this lipid in aging red blood cells presumably contributes to their removal from the circulation. In vitro stored red blood cells also suffer from the gradual appearance of PS at the outer surface in an amount proportional to the duration of storage.⁷⁹ Because aging cells progressively lose ATP-dependent enzymatic activities,¹⁷⁶^,¹⁷⁷ both Mg²⁺-ATP-dependent aminophospholipid translocase and the Ca²⁺ pump will be affected. Conceivably, this condition leads to increased cytoplasmic Ca²⁺ levels that stimulate lipid scramblase and suppress aminophospholipid translocase. Indeed, aminophospholipid transport activity decreases upon storage of red blood cells⁷⁸^,¹⁷⁸ and platelets.¹⁷⁹ Because oxidation affects the activity of membrane lipid transporters,²⁸^,¹⁷⁸^,^180-182 age-related alterations in the cells' redox state¹⁸³ may also contribute to PS exposure and cell recognition.

PS expression during apoptosis. Apoptosis, defined by characteristic morphologic alterations and DNA fragmentation, is also accompanied by exposure of PS at the cell's outer surface. This was first shown by the ability of apoptotic lymphocytes to shorten clotting times in the PS-dependent Russell viper venom coagulation assay and by labeling of surface exposed PS with fluorescamine.⁶ The observation was later confirmed by direct measurement of annexin V binding to different apoptotic cells.⁷^,⁸^,¹⁸⁴ Recent studies have shown convincingly that PS exposure is one of the earliest manifestations of apoptosis, and that it precedes DNA fragmentation, plasma membrane blebbing, and loss of membrane integrity.⁷ The process has been shown to be Ca²⁺-dependent and to involve bidirectional, nonspecific flip-flop of phospholipids.¹⁸⁵ Although a PS-specific reverse translocase has been suggested to be responsible for this process,⁷ there is no evidence that such a transporter exists. Because the appearance of PS in apoptosis shares features typical of the collapse of membrane phospholipid asymmetry in activated platelets, it is most likely that apoptotic cell membrane lipid asymmetry is compromised by the combined actions of an activated scramblase and inhibited translocase.²¹ Conceivably, these events could be accompanied by membrane unpacking, which has also been shown to precede DNA fragmentation.¹⁸⁶^,¹⁸⁷ This proposed mechanism is also consistent with the observation that calpain inhibitors prevent the characteristic blebbing and microvesiculation common to both platelet activation⁷² and apoptosis.¹⁸⁸

PS receptors in macrophages. The mechanisms of PS-mediated cellular recognition by macrophages probably involve several distinct pathways (Fig 1). Inflammatory macrophages can recognize PS-expressing apoptotic lymphocytes via a specific PS receptor that is inhibited by liposomes containing phosphatidyl-L-serine but not by other anionic phospholipids, including phosphatidyl-D-serine.⁶ Whether this receptor is the same as macrosialin (CD68),¹⁸⁹ the 94- to 97-kD membrane protein that binds PS-expressing cells and oxidized low-density lipoproteins,¹⁹⁰^,¹⁹¹ remains to be explored. A seemingly distinct macrophage receptor belonging to the class B scavenger receptor I and CD36 has recently been described.^192-194 Gene transfer of this receptor to nonphagocytic cells confers recognition for PS¹⁹² and apoptotic cells.¹⁹³ This less-specific receptor also recognizes a variety of modified proteins, including oxidized LDL. Antibodies could also contribute to the removal of PS-expressing cells.¹³ For example, antiphospholipid syndrome antibodies that recognize plasma proteins bound to PS-expressing cells (or their microvesicles) can be expected to bind avidly to macrophages via the cells' Fc receptor. Other data indicate that members of the selectin family of adhesion molecules bind PS,¹²⁶ suggesting that they can also function as PS receptors. In addition, $beta$ 2-glycoprotein-I binds to intravenously injected PS-containing liposomes,¹⁹⁵ suggesting that it could play a direct, antibody-independent role in the clearance of PS-expressing cells. It should be noted that PS-independent recognition mechanisms, including the vitronectin receptor ( $alpha$ V $beta$ 3 integrin) on bone marrow macrophages, are also involved in recognition and sequestration of apoptotic cells.¹⁴^,¹⁹⁶ The complexity of these recognition mechanisms is further illustrated by the observation that bone marrow macrophages can be stimulated to express the PS-binding characteristics of inflammatory macrophages.¹⁵ Lastly, it was recently reported that smooth muscle cells also recognize PS-expressing cells,⁸ suggesting that PS-dependent cell recognition is not limited to professional phagocytes.

  CONCLUSIONS

The lipid transporter-controlled emergence of PS in the cell's outer leaflet results in the expression of altered surface properties that influence and regulate the cell's interaction with its environment. PS clearly plays a pivotal role in maintaining the delicate balance between hemostasis and thrombosis as its overexpression generates potentially dangerous thrombogenic surfaces. It is therefore essential that distinct, albeit cooperative mechanisms for the recognition and removal of PS-expressing cells exist. Understanding these mechanisms, as well as those that generate and regulate membrane lipid sidedness and those that promote a collapse of phospholipid asymmetry, is a starting point from which the role of lipid transporters in disease can be assessed.

  FOOTNOTES

   Submitted June 24, 1996; accepted October 7, 1996.
   Supported in part by National Institutes of Health Grant No. DK41714.
   Address reprint requests to Alan J. Schroit, PhD, Department of Cell Biology, Box 173, The University of Texas M.D. Anderson Cancer Center, 1500 Holcomble Blvd, Houston, TX 77030.

  ACKNOWLEDGMENT

The authors dedicate this article to the memory of Mrs Mary Ann Scott. We thank Drs E.M. Bevers, Y. Killion, and P. Comfurius for comments and critical review of the manuscript and are grateful to L. Feldman for her editorial assistance.

  REFERENCES

Introduction
References

1. Seigneuret M, Devaux PF: Asymmetric distribution of spin-labeled phospholipids in the erythrocyte membrane: Relation to shape changes. Proc Natl Acad Sci USA 81:3751, 1984[Abstract/Free Full Text]
2. Bevers EM, Comfurius P, VanRijn JLML, Hemker HC, Zwaal RFA: Generation of prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem 122:429, 1982[Medline] [Order article via Infotrieve]
3. Bevers EM, Comfurius P, Zwaal RFA: Changes in membrane phospholipid distribution during platelet activation. Biochim Biophys Acta 736:57, 1983[Medline] [Order article via Infotrieve]
4. Zwaal RFA, Comfurius P, VanDeenen LLM: Membrane asymmetry and blood coagulation. Nature 268:358, 1977[Medline] [Order article via Infotrieve]
5. Zwaal RFA: Membrane and lipid involvement in blood coagulation. Biochim Biophys Acta 515:163, 1978[Medline] [Order article via Infotrieve]
6. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM: Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 148:2207, 1992[Abstract]
7. Martin SJ, Reutelingsperger CPM, McGahon AJ, Rader JA, VanSchie RCAA, Laface DM, Green DR: Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and Abl. J Exp Med 182:1545, 1995[Abstract/Free Full Text]
8. Bennett MR, Gibson DF, Schwartz SM, Tait JF: Binding and phagocytosis of apoptotic vascular smooth muscle cells is mediated in part by exposure of phosphatidylserine. Circ Res 77:1136, 1995[Abstract/Free Full Text]
9. Casciola-Rosen L, Rosen A, Petri M, Schlissel M: Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: Implications for coagulation events and antigenic spread in systemic lupus erythematosis. Proc Natl Acad Sci USA 93:1624, 1996[Abstract/Free Full Text]
10. Connor J, Bucana C, Fidler IJ, Schroit AJ: Differentiation-dependent expression of phosphatidylserine in mammalian plasma membranes: Quantitative assessment of outer leaflet lipid by prothrombinase complex formation PS asymmetry. Proc Natl Acad Sci USA 86:3184, 1991
11. Utsugi T, Schroit AJ, Connor J, Bucana CD, Fidler IJ: Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res 51:3062, 1991[Abstract/Free Full Text]
12. Tanaka Y, Schroit AJ: Insertion of fluorescent phosphatidylserine into the plasma membrane of red blood cells: Recognition by autologous macrophages. J Biol Chem 258:11335, 1983[Abstract/Free Full Text]
13. Schroit AJ, Madsen J, Tanaka Y:In vivo recognition and clearance of red blood cells containing phosphatidylserine in their plasma membranes. J Biol Chem 260:5131, 1985
14. Fadok VA, Savill JS, Haslett C, Bratton DL, Doherty DE, Campbell PA, Henson PM: Different populations of macrophages use either the vitronectin receptor or the phosphatidylserine receptor to recognize and remove apoptotic cells. J Immunol 149:4029, 1992[Abstract]
15. Fadok VA, Laszlo D, Noble PW, Weinstein L, Riches DWH, Henson PM: Particle digestibility is required for induction of the phosphatidylserine recognition mechanism used by murine macrophages to phagocytose apoptotic cells. J Immunol 151:4274, 1993[Abstract]
16. Schroit AJ, Zwaal RFA: Transbilayer movement of phospholipids in red cell and platelet membranes. Biochim Biophys Acta 1071:313, 1991[Medline] [Order article via Infotrieve]
17. Devaux PF: Protein involvement in transmembrane lipid asymmetry. Annu Rev Biophys Biomol Struct 21:417, 1992[Medline] [Order article via Infotrieve]
18. Devaux PF, Zachowski A: Maintenance and consequences of membrane phospholipid asymmetry. Chem Phys Lipids 73:107, 1994
19. Roelofsen B, OpdenKamp JAF: Plasma membrane phospholipid asymmetry and its maintenabce: The human erythrocyte as a model, in Hoekstra D (ed): Current Topics in Membranes, vol 40. New York, NY, Academic, 1994, p 7
20. Menon AK: Flippases. Trends Cell Biol 5:355, 1995[Medline] [Order article via Infotrieve]
21. Diaz C, Schroit AJ: Role of translocases in the generation of phosphatidylserine asymmetry. J Membr Biol 151:1, 1996[Medline] [Order article via Infotrieve]
22. Daleke DL, Huestis WH: Incorporation and translocation of aminophospholipids in human erythrocytes. Biochemistry 24:5406, 1985[Medline] [Order article via Infotrieve]
23. Connor J, Schroit AJ: Determination of lipid asymmetry in human red cells by resonance energy transfer. Biochemistry 26:5099, 1987[Medline] [Order article via Infotrieve]
24. Morrot G, Herve P, Zachowski A, Fellmann P, Devaux PF: Aminophospholipid translocase of human erythrocytes: Phospholipid substrate specificity and effect of cholesterol. Biochemistry 28:3456, 1989[Medline] [Order article via Infotrieve]
25. Connor J, Pak CH, Zwaal RFA, Schroit AJ: Bidirectional transbilayer movement of phospholipid analogs in human red blood cells. J Biol Chem 267:19412, 1992[Abstract/Free Full Text]
26. Beleznay Z, Zachowski A, Devaux PF, Navazo MP, Ott P: ATP-dependent aminophospholipid translocation in erythrocyte vesicles $---$ Stoichiometry of transport. Biochemistry 32:3146, 1994
27. Martin OC, Pagano RE: Transbilayer movement of fluorescent analogs of phosphatidylserine and phosphatidylethanolamine at the plasma membrane of cultured cells. J Biol Chem 262:5890, 1987[Abstract/Free Full Text]
28. Connor J, Schroit AJ: Transbilayer movement of phosphatidylserine in erythrocytes. Inhibition of transport and preferential labeling of a 31,000 Dalton protein by sulfhydryl reactive reagents. Biochemistry 27:848, 1988[Medline] [Order article via Infotrieve]
29. Connor J, Schroit AJ: Aminophospholipid translocation in erythrocytes: Evidence for the involvement of a specific transporter and an endofacial protein. Biochemistry 29:37, 1990[Medline] [Order article via Infotrieve]
30. Bitbol M, Fellmann P, Zachowski A, Devaux PF: Ion regulation of phosphatidylserine and phosphatidylethanolamine outside-inside translocation in human erythrocytes. Biochim Biophys Acta 904:268, 1987[Medline] [Order article via Infotrieve]
31. Tilly RHJ, Senden JMG, Comfurius P, Bevers EM, Zwaal RFA: Increased aminophospholipid translocase activity in human platelets during secretion. Biochim Biophys Acta 1029:188, 1990[Medline] [Order article via Infotrieve]
32. Morrot G, Zachowski A, Devaux PF: Partial purification and ch a racterization of the human Mg²⁺-ATPase: A candidate aminophospholipid translocase. FEBS Lett 266:29, 1990[Medline] [Order article via Infotrieve]
33. Zimmerman ML, Daleke DL: Regulation of a candidate aminophospholipid-transporting ATPase by lipid. Biochemistry 32:12257, 1993[Medline] [Order article via Infotrieve]
34. Auland ME, Morris MB, Roufogalis BD: Separation and characterization of two Mg(2+)-ATPase activities from the human erythrocyte membrane. Arch Biochem Biophys 312:272, 1994[Medline] [Order article via Infotrieve]
35. Auland ME, Roufogalis BD, Devaux PF, Zachowski A: Reconstitution of ATP-dependent aminophospholipid translocation in proteoliposomes. Proc Natl Acad Sci USA 91:10938, 1994[Abstract/Free Full Text]
36. Zachowski A, Dolis D, Moreau C, Devaux PF: Reconstitution of an aminophospholipid translocase activity in proteoliposomes. Conférence Jacques Monod (CNRS) 'Lipid diversity in membranes and cellular functions', La Londe les Maures, France. 1995, p 80 (abstr)
37. Schroit AJ, Madsen J, Ruoho AE: Radioiodinated, photoaffinity-labeled phosphatidylcholine and phosphatidylserine. Transfer properties and differential photoreactive reaction with human erythrocyte membrane proteins. Biochemistry 26:1812, 1987[Medline] [Order article via Infotrieve]
38. Connor J, Schroit AJ: Transbilayer movement of phosphatidylserine in non-human erythrocytes: Evidence that the aminophospholipid transporter is a ubiquitous membrane protein. Biochemistry 28:9680, 1989[Medline] [Order article via Infotrieve]
39. Schroit AJ, Bloy C, Connor J, Cartron JP: Involvement of Rh blood group polypeptides in the maintenance of aminophospholipid asymmetry. Biochemistry 29:10303, 1990[Medline] [Order article via Infotrieve]
40. Connor J, Schroit AJ: Transbilayer movement of phosphatidylserine in erythrocytes: Inhibitors of aminophospholipid transport block the association of photolabeled lipid to its transporter. Biochim Biophys Acta 1066:37, 1991[Medline] [Order article via Infotrieve]
41. Higgins CF: Flip-flop: The transmembrane translocation of lipids. Cell 79:393, 1994[Medline] [Order article via Infotrieve]
42. Higgins CF: P-glycoprotein. To flip or not to flip? Curr Biol 4:259, 1994[Medline] [Order article via Infotrieve]
43. Zachowski A, Henry JP, Devaux PF: Control of transmembrane lipid asymmetry in chromaffin granules by an ATP-dependent protein. Nature 340:75, 1989[Medline] [Order article via Infotrieve]
44. Herrmann A, Zachowski A, Devaux PF: Protein-mediated phospholipid translocation in the endoplasmatic reticulum with a low lipid specificity. Biochemistry 29:2023, 1990[Medline] [Order article via Infotrieve]
45. Sune A, Bette-Bobillo P, Bienvenue A, Fellmann P, Devaux PF: Selective outside-inside translocation of aminophospholipids in human platelets. Biochemistry 26:2972, 1987[Medline] [Order article via Infotrieve]
46. Smeets EF, Comfurius P, Bevers EM, Zwaal RFA: Calcium-induced transbilayer scrambling of fluorescent phospholipid analogs in platelets and erythrocytes. Biochim Biophys Acta 1195:281, 1994[Medline] [Order article via Infotrieve]
47. Zachowski A, Gaudry-Talarmain YM: Phospholipid transverse diffusion in synaptosomes: Evidence for the involvement of the aminophospholipid translocase. J Neurochem 55:1352, 1990[Medline] [Order article via Infotrieve]
48. Muller K, Labbe C, Zachowski A: Phospholipid transverse asymmetry in trout spermatozoa plasma membrane. Biochim Biophys Acta 1192:21, 1994[Medline] [Order article via Infotrieve]
49. Muller K, Pomorski T, Muller P, Zachowski A, Herrmann A: Protein-dependent translocation of aminophospholipids and asymmetric transbilayer distribution of phospholipids in the plasma membrane of ram sperm cells. Biochemistry 33:9968, 1994[Medline] [Order article via Infotrieve]
50. Pomorski T, Müller P, Zimmermann B, Burger K, Devaux PF, Herrmann A: Transbilayer movementof fluorescent and spin-labeled phospholipids in the plasma membrane of human fibroblasts: A quantitative approach. J Cell Sci 109:687, 1996[Abstract/Free Full Text]
51. Julien M, Tournier JF, Tocanne JF: Basic fibroblast growth factor modulates the aminophospholipid translocase activity present in the plasma membrane of bovine aortic endothelial cells. Eur J Biochem 230:287, 1995[Medline] [Order article via Infotrieve]
52. Hanada K, Pagano RE: A Chinese hamster ovary cell mutant defective in the non-endocytic uptake of fluorescent analogs of phosphatidylserine: Isolation using a cytosol acidification protocol. J Cell Biol 128:793, 1995[Abstract/Free Full Text]
53. Bitbol M, Devaux PF: Measurement of outward translocation of phospholipids across human erythrocyte membrane. Proc Nat Acad Sci USA 85:6783, 1988[Abstract/Free Full Text]
54. Connor J, Gillum K, Schroit AJ: Maintenance of lipid asymmetry in red blood cells and ghosts. Effect of divalent cations and serum albumin on the transbilayer distribution of phosphatidylserine. Biochim Biophys Acta 1025:82, 1990[Medline] [Order article via Infotrieve]
55. Andrick C, Broring K, Deuticke B, Haest CWM: Fast translocation of phosphatidylcholine to the outer membrane leaflet after its synthesis at the inner membrane surface in human erythrocytes. Biochim Biophys Acta 1064:235, 1991[Medline] [Order article via Infotrieve]
56. Sugihara T, Sugihara K, Hebbel RP: Phospholipid asymmetry during erythrocyte deformation: Maintenance of the unit membrane. Biochim Biophys Acta 1103:303, 1992[Medline] [Order article via Infotrieve]
57. Comfurius P, Senden JM, Tilly RH, Schroit AJ, Bevers EM, Zwaal RFA: Loss of membrane phospholipid asymmetry in platelets and red cells may be associated with calcium-induced shedding of plasma membrane and inhibition of aminophospholipid translocase. Biochim Biophys Acta 1026:153, 1990[Medline] [Order article via Infotrieve]
58. Devaux PF: Static and dynamic lipid asymmetry in cell membranes. Biochemistry 30:1163, 1991[Medline] [Order article via Infotrieve]
59. Lucy JA: Loss of phospholipid asymmetry in cell fusion. Biochem Soc Trans 21:280, 1993[Medline] [Order article via Infotrieve]
60. Farge E: Increased vesicle endocytosis due to an increase in the plasma membrane phosphatidylserine concentration. Biophys J 69:2501, 1995[Medline] [Order article via Infotrieve]
61. Zwaal RFA, Comfurius P, Bevers EM: Mechanism and function of changes in membrane-phospholipid asymmetry in platelets and erythrocytes. Biochem Soc Trans 21:248, 1993[Medline] [Order article via Infotrieve]
62. Rosing J, Bevers EM, Comfurius P, Hemker HC, VanDieijen G, Weiss HJ, Zwaal RFA: Impaired factor X and prothrombin activation associated with decreased phospholipid exposure in platelets from a patient with a bleeding disorder. Blood 65:1557, 1985[Abstract/Free Full Text]
63. Weiss HJ: Scott syndrome: A disorder of platelet coagulant activity. Semin Hematol 31:312, 1994[Medline] [Order article via Infotrieve]
64. Toti F, Satta N, Fressinaud E, Meyer D, Freyssinet JM: Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Blood 87:1409, 1996[Abstract/Free Full Text]
65. Williamson P, Bevers EM, Smeets EF, Comfurius P, Schlegel RA, Zwaal RFA: Continuous analysis of the mechanism of activated transbilayer lipid movement in platelets. Biochemistry 34:10448, 1995[Medline] [Order article via Infotrieve]
66. Williamson P, Kulick A, Zachowski A, Schlegel RA, Devaux PF: Ca²⁺ induces transbilayer redistribution of all major phospholipids in human erythrocytes. Biochemistry 31:6355, 1992[Medline] [Order article via Infotrieve]
67. Sulpice JC, Zachowski A, Devaux PF, Giraud F: Requirement for phosphatidylinos itol 4,5-bisphosphate in the Ca²⁺-induced phospholipid redistribution in the human erythrocyte membrane. J Biol Chem 269:6347, 1994[Abstract/Free Full Text]
68. Martin DW, Jesty J: Calcium stimulation of procoagulant activity in human erythrocytes. ATP dependence and the effects of modifiers of stimulation and recovery. J Biol Chem 270:10468, 1995[Abstract/Free Full Text]
69. Comfurius P, Williamson P, Smeets EF, Schlegel RA, Bevers EM, Zwaal RFA: Reconstitution of phospholipid scramblase activity from human blood platelets. Biochemistry 35:7631, 1996[Medline] [Order article via Infotrieve]
70. Bassé F, Stout JG, Sims PJ, Wiedmer T: Isolation of an erythrocyte membrane protein that mediates Ca²⁺-dependent transbilayer movement of phospholipid. J Biol Chem 271:17205, 1996[Abstract/Free Full Text]
71. Bevers EM, Wiedmer T, Comfurius P, Zhao J, Smeets EF, Schlegel RA, Schroit AJ, Weiss HJ, Williamson P, Zwaal RFA, Sims PJ: The complex of phosphatidylinositol 4,5-bisphosphate and calcium ions is not responsible for Ca²⁺-induced loss of phospholipid asymmetry in the human erythrocyte: A study in Scott syndrome, a disorder of calcium-induced phospholipid scrambling. Blood 86:1983, 1995[Abstract/Free Full Text]
72. Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ: Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: An isolated defect in platelet procoagulant activity. J Biol Chem 264:17049, 1989[Abstract/Free Full Text]
73. Wiedmer T, Shattil SJ, Cunningham M, Sims PJ: Role of calcium and calpain in complement-induced vesiculation of the platelet plasma membrane and in the exposure of the platelet factor Va receptor. Biochemistry 29:623, 1990[Medline] [Order article via Infotrieve]
74. Zwaal RFA, Comfurius P, Bevers EM: Platelet procoagulant activity and microvesicle formation. Its putative role in hemostasis and thrombosis. Biochim Biophys Acta 1180:1, 1992[Medline] [Order article via Infotrieve]
75. Dachary-Prigent J, Freyssinet JM, Pasquet JM, Carron JC, Nurden AT: Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: A flow cytometry study showing a role for free sulfhydryl groups. Blood 81:2554, 1993[Abstract/Free Full Text]
76. Fox JEB, Austin CD, Reynolds C, Steffen PK: Evidence that agonist-induced activation of calpain causes the shedding of procoagulant-containing microvesicles from the membrane of aggregating platelets. J Biol Chem 266:13289, 1991[Abstract/Free Full Text]
77. Dachary-Prigent J, Pasquet JM, Freyssinet JM, Nurden AT: Calcium involvement in aminophospholipid exposure and microparticle formation during platelet activation: A study using Ca²⁺-ATPase inhibitors. Biochemistry 34:11625, 1995[Medline] [Order article via Infotrieve]
78. Geldwerth D, Kuypers FA, Butikofer P, Allary M, Lubin BH, Devaux PF: Transbilayer mobility and distribution of red cell phospholipids during storage. J Clin Invest 93:92, 1993
79. Tait JF, Gibson D: Measurement of membrane phospholipid asymmetry in normal and sickle-cell erythrocytes by means of annexin V binding. J Lab Clin Med 123:741, 1994[Medline] [Order article via Infotrieve]
80. Sestier C, Sabolovic D, Geldwerth D, Moumaris M, Roger J, Pons JN, Halbreich A: Use of annexin V-ferrofluid to enumerate erythrocytes damaged in various pathologies or during storage in vitro. CR Acad Sci III 318:1141, 1995
81. Chiu D, Lubin B, Shohet SB: Erythrocyte membrane lipid reorganization during the sickling process. Br J Haematol 41:223, 1979[Medline] [Order article via Infotrieve]
82. Chiu D, Lubin B, Roelofsen B, VanDeenen LLM: Sickled erythrocytes accelerate clotting in vitro: An effect of abnormal membrane lipid asymmetry. Blood 58:398, 1981[Abstract/Free Full Text]
83. Kuypers FA, Lewis RA, Hua M, Schott MA, Discher D, Ernst JD, Lubin BH: Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently-labeled annexin V. Blood 87:1179, 1996[Abstract/Free Full Text]
84. Liu SC, Yi SJ, Mehta JR, Nichols PE, Ballas SK, Yacono PW, Golan DE, Palek J: Red cell membrane remodeling in sickle cell anemia. Sequestration of membrane lipids and proteins in Heinz bodies. J Clin Invest 97:29, 1996[Medline] [Order article via Infotrieve]
85. Wali RK, Jaffe S, Kumar D, Kalra VK: Alterations in organization of phospholipids in erythrocytes as factor in adherence to endothelial cells in diabetes mellitus. Diabetes 37:104, 1988[Abstract]
86. Wilson MJ, Richterlowney K, Daleke DL: Hyperglycemia induces a loss of phospholipid asymmetry in human erythrocytes. Biochemistry 32:11302, 1993[Medline] [Order article via Infotrieve]
87. Connor J, Pak CC, Schroit AJ: Exposure of phosphatidylserine in the outer leaflet of human red blood cells: Relationship to cell density, cell age, and clearance by mononuclear cells. J Biol Chem 269:2399, 1994[Abstract/Free Full Text]
88. Diaz C, Morkowski J, Schroit AJ: Generation of phenotypically aged phosphatidylserine-expressing erythrocytes by dilauroylphosphatidylcholine-induced vesiculation. Blood 87:2956, 1996[Abstract/Free Full Text]
89. Haest CWM, Plasa G, Kamp D, Deuticke B: Spectrin as a stabilizer of the phospholipid asymmetry in the human erythrocyte membrane. Biochim Biophys Acta 509:21, 1978[Medline] [Order article via Infotrieve]
90. Haest CWM: Interactions between membrane skeleton proteins and the intrinsic domain of the erythrocyte membrane. Biochim Biophys Acta 694:331, 1982[Medline] [Order article via Infotrieve]
91. Franck PFH, Bevers EM, Lubin BH, Comfurius P, Chiu DT-Y, OpDenKamp JAF, Zwaal RFA, VanDeenen LLM, Roelofsen B: Uncoupling of the membrane skeleton from the lipid bilayer: The cause of accelerated phospholipid flip-flop leading to enhanced procoagulant activity of sickled cells. J Clin Invest 75:183, 1985
92. Calvez J-Y, Zachowski A, Herrmann A, Morrot G, Devaux PF: Asymmetric distribution of phospholipids in spectrin-poor erythrocyte vesicles. Biochemistry 27:5666, 1988[Medline] [Order article via Infotrieve]
93. Bruckheimer EB, Gillum KD, Schroit AJ: Co-localization of Rh polypeptides and the aminophospholipid transporter in dilauroylphosphatidylcholine-induced erythrocyte vesicles. Biochim Biophys Acta 1235:147, 1995[Medline] [Order article via Infotrieve]
94. Kuypers FA, Lubin BH, Yee M, Agre P, Devaux PF, Geldwerth D: The distribution of erythrocyte phospholipids in hereditary spherocytosis demonstrates a minimal role for erythrocyte spectrin on phospholipid diffusion and asymmetry. Blood 81:1051, 1993[Abstract/Free Full Text]
95. Smit JJM, Schinkel AH, Oude Elferink RPJ, Groen AK, Wagenaar E, VanDeemter L, Mol CAAM, Ottenhoff R, VanDerLugt NM, VanRoon MA, VanDerValk MA, Offerhaus GJA, Berns AJM, Borst P: Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75:451, 1993[Medline] [Order article via Infotrieve]
96. Oude Elferink RPJ, Groen AK: The role of mdr2 P-glycoprotein in biliary lipid secretion. Cross-talk between cancer research and biliary physiology. J Hepatol 23:617, 1995[Medline] [Order article via Infotrieve]
97. Higgins CF, Gottesman MM: Is the multidrug transporter a flippase? Trends Biochem Sci 17:18, 1992[Medline] [Order article via Infotrieve]
98. Homolya L, Hollo Z, Germann UA, Pastan I, Gottesman MM, Sarkadi B: Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 268:21493, 1993[Abstract/Free Full Text]
99. Basse F, Gaffet P, Rendu F, Bienvenue A: Translocation of spin-labeled phospholipids through plasma membrane during thrombin-induced and ionophore-A23187-induced platelet activation. Biochemistry 32:2337, 1993[Medline] [Order article via Infotrieve]
100. Gaffet P, Bettache N, Bienvenue A: Transverse redistribution of phospholipids during human platelet activation: Evidence for a vectorial outflux specific to aminophospholipids. Biochemistry 34:6762, 1995[Medline] [Order article via Infotrieve]
101. Chang CP, Zhao J, Wiedmer T, Sims PJ: Contribution of platelet microparticle formation and granule secretion to the transmembrane migration of phosphatidylserine. J Biol Chem 268:7171, 1993[Abstract/Free Full Text]
102. Bevers EM, Wiedmer T, Comfurius P, Shattil SJ, Weiss HJ, Zwaal RFA, Sims PJ: Defective Ca²⁺-induced microvesiculation and deficient expression of procoagulant activity in erythrocytes from a patient with a bleeding disorder: A study of the red blood cells of Scott syndrome. Blood 79:380, 1992[Abstract/Free Full Text]
103. Farge E, Devaux PF: Shape changes of giant liposomes induced by an asymmetric transmembrane distribution of phospholipids. Biophys J 61:347, 1992[Medline] [Order article via Infotrieve]
104. Nemerson Y: The tissue factor pathway of blood coagulation. Semin Hematol 29:170, 1992[Medline] [Order article via Infotrieve]
105. Esmon CT: Cell mediated events that control blood coagulation and vascular injury. Annu Rev Cell Biol 9:1, 1993
106. Kalafatis M, Swords NA, Rand MD, Mann KG: Membrane-dependent reactions in blood coagulation: Role of the vitamin K-dependent enzyme complexes. Biochim Biophys Acta 1227:113, 1994[Medline] [Order article via Infotrieve]
107. Andree HAM, Nemerson Y: Tissue factor: Regulation of activity by flow and phospholipid surfaces. Blood Coagul Fibrinol 6:189, 1995[Medline] [Order article via Infotrieve]
108. Bach R, Gentry R, Nemerson Y: Factor VII binding to tissue factor in reconstituted phospholipid vesicles: Induction of cooperativity by phosphatidylserine. Biochemistry 25:4007, 1986[Medline] [Order article via Infotrieve]
109. Bach R, Rifkin DB: Expression of tissue factor procoagulant activity: Regulation by cytosolic calcium. Proc Natl Acad Sci USA 87:6995, 1990[Abstract/Free Full Text]
110. Ruf W, Rehemtulla A, Morrissey JH, Edgington TS: Phospholipid-independent and dependent interactions required for tissue factor receptor and cofactor function. J Biol Chem 266:2158, 1991[Abstract/Free Full Text]
111. Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S: Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 76:1, 1990[Abstract/Free Full Text]
112. Rosing J, Speijer H, Zwaal RFA: Prothrombin activation on phospholipid membranes with positive electrostatic potential. Biochemistry 27:8, 1988[Medline] [Order article via Infotrieve]
113. Gilbert GE, Drinkwater D: Specific membrane binding of factor VIII is mediated by O-phospho-L-serine, a moiety of phosphatidylserine. Biochemistry 32:9577, 1993[Medline] [Order article via Infotrieve]
114. Comfurius P, Smeets EF, Willems GM, Bevers EM, Zwaal RFA: Assembly of the prothrombinase complex on lipid vesicles depends on the stereochemical configuration of the polar headgroup of phosphatidylserine. Biochemistry 33:10319, 1994[Medline] [Order article via Infotrieve]
115. Tans G, Rosing J, Thomassen MCLGD, Heeb MJ, Zwaal RFA, Griffin JH: Comparison of anticoagulant and procoagulant properties of stimulated platelets and platelet-derived microparticles. Blood 77:2641, 1991[Abstract/Free Full Text]
116. Bevers EM, Comfurius P, Zwaal RFA: The nature of the binding site for prothrombinase at the platelet surface as revealed by lipolytic enzymes. Eur J Biochem 122:81, 1982[Medline] [Order article via Infotrieve]
117. Thiagarajan P, Tait JF: Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. J Biol Chem 265:17420, 1990[Abstract/Free Full Text]
118. Rao LV, Tait JF, Hoang AD: Binding of annexin V to a human ovarian carcinoma cell line (OC-2008). Contrasting effects on cell surface factor VIIa/tissue factor activity and prothrombinase activity. Thromb Res 67:517, 1992[Medline] [Order article via Infotrieve]
119. Rosing J, VanRijn JLML, Bevers EM, VanDieijen G, Comfurius P, Zwaal RFA: The role of activated human platelets in prothrombin and factor X activation. Blood 65:319, 1985[Abstract/Free Full Text]
120. Zwaal RFA, Bevers EM, Comfurius P, Rosing J, Tilly RHJ, Verhallen PFJ: Loss of membrane phospholipid asymmetry during activation of blood platelets and sickled red cells: Mechanism and physiological significance. Mol Cell Biochem 91:23, 1989[Medline] [Order article via Infotrieve]
121. Sims PJ, Faioni EM, Wiedmer T, Shattil SJ: Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 263:18205, 1988[Abstract/Free Full Text]
122. Holme PA, Solum NO, Brosstad F, Roger M, Abdelnoor M: Demonstration of platelet-derived microvesicles in blood from patients with activated coagulation and fibrinolysis using a filtration technique and Western blotting. Thromb Haemost 72:666, 1994[Medline] [Order article via Infotrieve]
123. Lee Y, Jy W, Horstman LL, Janania J , Kelley R, Ahn YS: Elevated platelet microparticles in multiinfarct dementias and transient ischemic attacks. Thromb Res 72:295, 1993[Medline] [Order article via Infotrieve]
124. Jy W, Horstman LL, Wang F, Duncan R, Ahn YS: Platelet factor 3 in plasma fractions: Its relation to microparticle size and thromboses. Thromb Res 80:471, 1995[Medline] [Order article via Infotrieve]
125. Jy W, Mao WW, Horstman LL, Tao J, Ahn YS: Platelet microparticles bind, activate and aggregate neutrophils in vitro. Blood Cells Mol Dis 21:217, 1995[Medline] [Order article via Infotrieve]
126. Malhotra R, Taylor NR, Bird MI: Anionic phospholipids bind to L-selectin (but not E-selectin) at a site distinct from the carbohydrate-binding site. Biochem J 314:297, 1996
127. Bona R, Lee E, Rickles F: Tissue factor apoprotein: Intracellular transport and expression in shed membrane vesicles. Thromb Res 48:487, 1987[Medline] [Order article via Infotrieve]
128. Dvorak HF, Van DeWater L, Bitzer AM, Dvorak AM, Anderson D, Harvey VS, Bach R, Davis GL, DeWolf W, Carvalho AC: Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res 43:4434, 1983[Abstract/Free Full Text]
129. Weiss HJ, Vivic WJ, Lages BA, Rogers J: Isolated deficiency of platelet procoagulant activity. Am J Med 67:206, 1979[Medline] [Order article via Infotrieve]
130. Miletich JP, Kane WH, Hofmann SL, Stanford N, Majerus PW: Deficiency of factor Xa-factor Va binding sites on the platelets of a patient with a bleeding disorder. Blood 54:1015, 1979[Abstract/Free Full Text]
131. Ahmad SS, Rawala-Sheikh R, Ashby B, Walsh PN: Platelet receptor-mediated factor X activation by factor IXa. High-affinity factor IXa receptors induced by factor VIII are deficient on platelets in Scott Syndrome. J Clin Invest 84:824, 1989
132. Kojima H, Newton-Nash D, Weiss HJ, Zhao J, Sims PJ, Wiedmer T: Production and characterization of transformed B-lymphocytes expressing the membrane defect of Scott syndrome. J Clin Invest 94:2237, 1994
133. Chandra R, Joshi PC, Bajpaj VK, Gupta CM: Membrane phospholipid organization in calcium-loaded human erythrocytes. Biochim Biophys Acta 902:253, 1987[Medline] [Order article via Infotrieve]
134. Lupu C, Calb M, Ionescu M, Lupu F: Enhanced prothrombin and intrinsic factor X activation on blood platelets from diabetic patients. Thromb Haemost 70:579, 1993[Medline] [Order article via Infotrieve]
135. Epand RM, Stafford A, Leon B, Lock PE, Tytler EM, Segrest JP, Anantharamaiah GM: HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity. Arterioscler Thromb 14:1775, 1994[Abstract/Free Full Text]
136. Tracy PB, Eide LL, Mann KG: Human prothrombinase complex assembly and function on isolated peripheral blood cell populations. J Biol Chem 260:2119, 1985[Abstract/Free Full Text]
137. Tracy PB: Regulation of thrombin generation at cell surfaces. Semin Thromb Haemost 14:227, 1988
138. Robinson RA, Worfolk L, Tracy PB: Endotoxin enhances the expression of monocyte prothrombinase activity. Blood 79:406, 1992[Abstract/Free Full Text]
139. Satta N, Toti F, Feugeas O, Bohbot A, Dachary-Prigent J, Eschwège V, Hedman H, Freyssinet JM: Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharides. J Immunol 153:3245, 1994[Abstract]
140. Gregory SA, Morrissey JH, Edgington TS: Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Biol 9:2752, 1989[Abstract/Free Full Text]
141. Rapaport SI, Rao LVM: Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb 12:1111, 1992[Medline] [Order article via Infotrieve]
142. Hamilton KK, Hattori R, Esmon CT, Sims PJ: Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 265:3809, 1990[Abstract/Free Full Text]
143. VanDeMeer BW, Fugate RD, Sims PJ: Complement proteins C5b-9 induce transbilayer migration of membrane phospholipids. Biophys J 56:935, 1989[Medline] [Order article via Infotrieve]
144. Fattal E, Nir S, Parente RA, Szoka FC: Pore-forming peptides induce rapid phospholipid flip-flop in membranes. Biochemistry 33:6721, 1994[Medline] [Order article via Infotrieve]
145. Almers W: Exocytosis. Annu Rev Physiol 52:607, 1990[Medline] [Order article via Infotrieve]
146. Andoh K, Kubota T, Takada M, Tanaka H, Kobayashi N, Maekawa T: Tissue factor activity in leukemia cells. Special reference to disseminated intravascular coagulation. Cancer 59:748, 1987[Medline] [Order article via Infotrieve]
147. Bauer KA, Conway EM, Bach R, Konigsberg WH, Griffin JD, Demetri G: Tissue factor gene expression in acute myeloblastic leukemia. Thromb Res 56:425, 1989[Medline] [Order article via Infotrieve]
148. Tallman MS, Kwaan HC: Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 79:543, 1992[Free Full Text]
149. Falanga A, Gordon SG: Isolation and characterization of cancer procoagulant: A cysteine proteinase from malignant tissue. Biochemistry 24:5558, 1985[Medline] [Order article via Infotrieve]
150. Donati MB, Gambacorti-Passerini C, Casali B, Falanga A, Vannotti P, Fossati G, Semeraro N, Gordon SG: Cancer procoagulant in human tumor cells: Evidence from melanoma patients. Cancer Res 46:6471, 1986[Abstract/Free Full Text]
151. Falanga A, Iacoviello L, Evangelista V, Belotti D, Consonni R, D'Orazio A, Robba L, Donati MB, Barbui T: Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. Blood 86:1072, 1995[Abstract/Free Full Text]
152. VanDeWater L, Tracy PB, Aronson D, Mann KG, Dvorak HF: Tumor cell generation of thrombin via functional prothrombinase assembly. Cancer Res 45:5521, 1985[Abstract/Free Full Text]
153. Sugimura M, Donato R, Kakkar VV, Scully MF: Annexin V as a probe of the contribution of anionic phospholipids to the procoagulant activity of tumor cell surfaces. Blood Coagul Fibrinol 5:365, 1994[Medline] [Order article via Infotrieve]
154. Bastida E, Ordinas A, Escolar G, Jamieson GA: Tissue factor in microvesicles shed from U87MG human glioblastoma cells induces coagulation, platelet aggregation, and thrombogenesis. Blood 64:177, 1984[Abstract/Free Full Text]
155. McNeil HP, Chesterman CN, Krilis SA: Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 49:193, 1991[Medline] [Order article via Infotrieve]
156. Roubey RA: Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 84:2854, 1994[Free Full Text]
157. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA: Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: $beta$ 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 87:4120, 1990[Abstract/Free Full Text]
158. Galli M, Comfurius P, Maassen C, Hemker HC, DeBaets MH, VanBreda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM: Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335:1544, 1990[Medline] [Order article via Infotrieve]
159. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA: Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 66:629, 1991[Medline] [Order article via Infotrieve]
160. Oosting JD, Derksen RH, Bobbink IW, Hackeng TM, Bouma BN, DeGroot PG: Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanism? Blood 81:2618, 1993[Abstract/Free Full Text]
161. Permpikul P, Rao LV, Rapaport SI: Functional and binding studies of the roles of prothrombin and $beta$ 2-glycoprotein I in the expression of lupus anticoagulant activity. Blood 83:2878, 1994[Abstract/Free Full Text]
162. Pengo V, Biasiolo A, Brocco T, Tonetto S, Ruffatti A: Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 75:721, 1996[Medline] [Order article via Infotrieve]
163. Galli M, Bevers EM, Comfurius P, Barbui T, Zwaal RFA: Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles. Br J Haematol 83:466, 1993[Medline] [Order article via Infotrieve]
164. Ciaudo M, Horellou MH, Audouin J, De Carbonnieres C, Conard J, Samama M: Lupus anticoagulant associated with primary malignant lymphoplasmacytic lymphoma of the spleen: A report of four patients. Am J Hematol 38:271, 1991[Medline] [Order article via Infotrieve]
165. Fidler IJ, Schroit AJ: Recognition and destruction of neoplastic cells by activated macrophages. Discrimination of altered self. Biochim Biophys Acta 948:151, 1988[Medline] [Order article via Infotrieve]
166. Pak CC, Fidler IJ: Molecular mechanisms for activated macrophage recognition of tumor cells. Semin Cancer Biol 2:189, 1991[Medline] [Order article via Infotrieve]
167. Poste G, Bucana C, Raz A, Bugelski P, Kirsh R, Fidler IJ: Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res 42:1412, 1982[Abstract/Free Full Text]
168. Raz A, Bucana C, Fogler WE, Poste G, Fidler IJ: Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages. Cancer Res 41:487, 1981[Abstract/Free Full Text]
169. Schroit AJ, Fidler IJ: Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by muramyl dipeptide liposomes. Cancer Res 42:161, 1982[Abstract/Free Full Text]
170. Lane A, O'Connell JL, Marlar RA: Erythrocyte membrane vesicles and irreversibly sickled cells bind protein. Am J Hematol 47:295, 1994[Medline] [Order article via Infotrieve]
171. Borenstain-Ben Yashar V, Barenholz Y, Hy-Am E, Rachmilewitz EA, Eldor A: Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am J Hematol 44:63, 1993[Medline] [Order article via Infotrieve]
172. Blumenfeld N, Zachowski A, Galacteros F, Beuzard Y, Devaux PF: Transmembrane mobility of phospholipids in sickle erythrocytes: Effect of deoxygenation on diffusion and asymmetry. Blood 77:849, 1991[Abstract/Free Full Text]
173. Muller P, Zachowski A, Beuzard Y, Devaux PF: Transmembrane mobility and distribution of phospholipids in the membrane of mouse beta-thalassaemic red blood cells. Biochim Biophys Acta 1151:7, 1993[Medline] [Order article via Infotrieve]
174. Schwartz RS, Tanaka Y, Fidler IJ, Chiu D, Lubin B, Schroit AJ: Increased adherence of sickled and phosphatidylserine enriched human erythrocytes to cultured human peripheral blood monocytes. J Clin Invest 75:1965, 1985
175. Pak CC, Fidler IJ: Activated macrophages distinguish undifferentiated-tumorigenic from differentiated-nontumorigenic murine erythroleukemia cells. Differentiation 41:49, 1989[Medline] [Order article via Infotrieve]
176. Bartosz G: Erythrocyte aging: Physical and chemical membrane changes. Gerontology 37:33, 1991[Medline] [Order article via Infotrieve]
177. Piomelli S, Seaman C: Mechanism of red blood cell aging: Relationship of cell density and cell age. Am J Hematol 42:46, 1993[Medline] [Order article via Infotrieve]
178. Herrmann A, Devaux PF: Alteration of the aminophospholipid translocase activity during in vivo and artificial aging of human erythrocytes. Biochim Biophys Acta 1027:41, 1990[Medline] [Order article via Infotrieve]
179. Gaffet P, Basse F, Bienvenue A: Loss of phospholipid asymmetry in human platelet plasma membrane after 1-12 days of storage. An ESR study. Eur J Biochem 222:1033, 1994[Medline] [Order article via Infotrieve]
180. Jain SK: The accumulation of malonyldialdehyde, a product of fatty acid peroxidation, can disturb aminophospholipid organization in the membrane bilayer of human erythrocytes. J Biol Chem 259:3391, 1984[Abstract/Free Full Text]
181. Jain SK: In vivo externalization of phosphatidylserine and phosphatidylethanolamine in the membrane bilayer and hypercoagulability by the lipid peroxidation of erythrocytes in rats. J Clin Invest 76:281, 1985
182. Bevers EM, Tilly RH, Senden JM, Comfurius P, Zwaal RFA: Exposure of endogenous phosphatidylserine at the outer surface of stimulated platelets is reversed by restoration of aminophospholipid translocase activity. Biochemistry 28:2382, 1989[Medline] [Order article via Infotrieve]
183. Jain SK: Evidence for membrane lipid peroxidation during the in vivo aging of human erythrocytes. Biochim Biophys Acta 937:205, 1988[Medline] [Order article via Infotrieve]
184. Koopman G, Reutelingsperger CPM, Kuijten GAM, Keehnen RMJ, Pals ST, VanOers MHJ: Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84:1415, 1994[Abstract/Free Full Text]
185. Verhoven B, Schlegel RA, Williamson P: Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal on apoptotic T lymphocytes. J Exp Med 182:1597, 1995[Abstract/Free Full Text]
186. Mower DA, Peckham DW, Illera VA, Fishbaugh JK, Stunz LL, Ashman RF: Decreased membrane phospholipid packing and decreased cell size precede DNA cleavage in mature mouse B cell apoptosis. J Immunol 152:4832, 1994[Abstract]
187. Ashman RF, Peckham D, Alhasan S, Stunz LL: Membrane unpacking and rapid disposal of apoptotic cells. Immunol Lett 48:159, 1995[Medline] [Order article via Infotrieve]
188. Squier MK, Miller AC, Malkinson AM, Cohen JJ: Calpain activation in apoptosis. J Cell Physiol 159:229, 1994[Medline] [Order article via Infotrieve]
189. Ramprasad MP, Fischer W, Witztum JL, Sambrano GR, Quehenberger O, Steinberg D: The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68. Proc Natl Acad Sci USA 92:9580, 1995[Abstract/Free Full Text]
190. Ottnad E, Parthasarathy S, Sambrano GR, Ramprasad MP, Quehenberger O, Kondratenko N, Green S, Steinberg D: A macrophage receptor for oxidized low density lipoprotein distinct from the receptor for acetyl low density lipoprotein: Partial purification and role in recognition of oxidatively damaged cells. Proc Natl Acad Sci USA 92:1391, 1995[Abstract/Free Full Text]
191. Sambrano GR, Steinberg D: Recognition of oxidatively damaged and apoptotic cells by an oxidized low density lipoprotein receptor on mouse peritoneal macrophages: Role of membrane phosphatidylserine. Proc Natl Acad Sci USA 92:1396, 1995[Abstract/Free Full Text]
192. Rigotti A, Acton SL, Krieger M: The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids. J Biol Chem 270:16221, 1995[Abstract/Free Full Text]
193. Ren Y, Silverstein RL, Allen J, Savill J: CD36 gene transfer confers capacity for phagocytosis of cells undergoing apoptosis. J Exp Med 181:1857, 1995[Abstract/Free Full Text]
194. Fukasawa M, Adachi H, Hirota K, Tsujimoto M, Arai H, Inoue K: SRB1, a class B scavenger receptor, recognizes both negatively charged liposomes and apoptotic cells. Exp Cell Res 222:246, 1996[Medline] [Order article via Infotrieve]
195. Chonn A, Semple SC, Cullis PR: Beta 2 glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of "non-self" particles. J Biol Chem 270:25845, 1995[Abstract/Free Full Text]
196. Savill J, Fadok V, Henson P, Haslett C: Phagocyte recognition of cells undergoing apoptosis. Immunol Today 14:131, 1993[Medline] [Order article via Infotrieve]

© 1997 by The American Society of Hematology.

Add to CiteULike CiteULike    Add to Connotea Connotea    Add to Del.icio.us Del.icio.us    Add to Digg Digg    Add to Reddit Reddit    Add to Technorati Technorati    What's this?

This article has been cited by other articles:

K. I. Ataga
Hypercoagulability and thrombotic complications in hemolytic anemias
Haematologica, November 1, 2009; 94(11): 1481 - 1484.
[Full Text] [PDF]

X. Zhou and T. R. Graham
Reconstitution of phospholipid translocase activity with purified Drs2p, a type-IV P-type ATPase from budding yeast
PNAS, September 29, 2009; 106(39): 16586 - 16591.
[Abstract] [Full Text] [PDF]

F. G. Blankenberg
Imaging the Molecular Signatures of Apoptosis and Injury with Radiolabeled Annexin V
Proceedings of the ATS, August 15, 2009; 6(5): 469 - 476.
[Abstract] [Full Text] [PDF]

A. Makovitzki, A. Fink, and Y. Shai
Suppression of Human Solid Tumor Growth in Mice by Intratumor and Systemic Inoculation of Histidine-Rich and pH-Dependent Host Defense-like Lytic Peptides
Cancer Res., April 15, 2009; 69(8): 3458 - 3463.
[Abstract] [Full Text] [PDF]

A. Bjorstad, G. Askarieh, K. L. Brown, K. Christenson, H. Forsman, K. Onnheim, H.-N. Li, S. Teneberg, O. Maier, D. Hoekstra, et al.
The Host Defense Peptide LL-37 Selectively Permeabilizes Apoptotic Leukocytes
Antimicrob. Agents Chemother., March 1, 2009; 53(3): 1027 - 1038.
[Abstract] [Full Text] [PDF]

S. K. Dasgupta, H. Abdel-Monem, P. Niravath, A. Le, R. V. Bellera, K. Langlois, S. Nagata, R. E. Rumbaut, and P. Thiagarajan
Lactadherin and clearance of platelet-derived microvesicles
Blood, February 5, 2009; 113(6): 1332 - 1339.
[Abstract] [Full Text] [PDF]

N. Mohandas and P. G. Gallagher
Red cell membrane: past, present, and future
Blood, November 15, 2008; 112(10): 3939 - 3948.
[Abstract] [Full Text] [PDF]

S. Sadallah, C. Eken, and J. A. Schifferli
Erythrocyte-derived ectosomes have immunosuppressive properties
J. Leukoc. Biol., November 1, 2008; 84(5): 1316 - 1325.
[Abstract] [Full Text] [PDF]

T. Yabu, S. Imamura, M. Yamashita, and T. Okazaki
Identification of Mg2+-dependent Neutral Sphingomyelinase 1 as a Mediator of Heat Stress-induced Ceramide Generation and Apoptosis
J. Biol. Chem., October 31, 2008; 283(44): 29971 - 29982.
[Abstract] [Full Text] [PDF]

T. Doue, K. Ohtsuki, K. Ogawa, M. Ueda, A. Azuma, H. Saji, H. W. Strauss, and H. Matsubara
Cardioprotective Effects of Erythropoietin in Rats Subjected to Ischemia-Reperfusion Injury: Assessment of Infarct Size with 99mTc-Annexin V
J. Nucl. Med., October 1, 2008; 49(10): 1694 - 1700.
[Abstract] [Full Text] [PDF]

M. Jayachandran, R. D. Litwiller, W. G. Owen, J. A. Heit, T. Behrenbeck, S. L. Mulvagh, P. A. Araoz, M. J. Budoff, S. M. Harman, and V. M. Miller
Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women
Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H931 - H938.
[Abstract] [Full Text] [PDF]

S. D. Turco, G. Basta, G. Lazzerini, M. Evangelista, G. Rainaldi, P. Tanganelli, J. H. Christensen, E. B. Schmidt, and R. De Caterina
Effect of the administration of n-3 polyunsaturated fatty acids on circulating levels of microparticles in patients with a previous myocardial infarction
Haematologica, June 1, 2008; 93(6): 892 - 899.
[Abstract] [Full Text] [PDF]

F. G. Blankenberg
In Vivo Detection of Apoptosis
J. Nucl. Med., June 1, 2008; 49(Suppl_2): 81S - 95S.
[Abstract] [Full Text] [PDF]

A.-l. Stahl, F. Vaziri-Sani, S. Heinen, A.-C. Kristoffersson, K.-H. Gydell, R. Raafat, A. Gutierrez, O. Beringer, P. F. Zipfel, and D. Karpman
Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation
Blood, June 1, 2008; 111(11): 5307 - 5315.
[Abstract] [Full Text] [PDF]

D. Smrz, P. Lebduska, L. Draberova, J. Korb, and P. Draber
Engagement of Phospholipid Scramblase 1 in Activated Cells: IMPLICATION FOR PHOSPHATIDYLSERINE EXTERNALIZATION AND EXOCYTOSIS
J. Biol. Chem., April 18, 2008; 283(16): 10904 - 10918.
[Abstract] [Full Text] [PDF]

M.-F. Penet, M. Abou-Hamdan, N. Coltel, E. Cornille, G. E. Grau, M. de Reggi, and B. Gharib
Protection against cerebral malaria by the low-molecular-weight thiol pantethine
PNAS, January 29, 2008; 105(4): 1321 - 1326.
[Abstract] [Full Text] [PDF]

C. Eken, O. Gasser, G. Zenhaeusern, I. Oehri, C. Hess, and J. A. Schifferli
Polymorphonuclear Neutrophil-Derived Ectosomes Interfere with the Maturation of Monocyte-Derived Dendritic Cells
J. Immunol., January 15, 2008; 180(2): 817 - 824.
[Abstract] [Full Text] [PDF]

K. I. Ataga, C. G. Moore, C. A. Hillery, S. Jones, H. C. Whinna, D. Strayhorn, C. Sohier, A. Hinderliter, L. V. Parise, and E. P. Orringer
Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension
Haematologica, January 1, 2008; 93(1): 20 - 26.
[Abstract] [Full Text] [PDF]

Y. Wang, W. Beck, R. Deppisch, S. M. Marshall, N. A. Hoenich, and M. G. Thompson
Differential effects of dialysis and ultrafiltrate from individuals with CKD, with or without diabetes, on platelet phosphatidylserine externalization
Am J Physiol Renal Physiol, January 1, 2008; 294(1): F220 - F228.
[Abstract] [Full Text] [PDF]

O. Simakova and N. J. Arispe
The Cell-Selective Neurotoxicity of the Alzheimer's A Peptide Is Determined by Surface Phosphatidylserine and Cytosolic ATP Levels. Membrane Binding Is Required for A Toxicity
J. Neurosci., December 12, 2007; 27(50): 13719 - 13729.
[Abstract] [Full Text] [PDF]

P. Baumgartner, M. Geiger, S. Zieseniss, J. Malleier, J. A. Huntington, K. Hochrainer, E. Bielek, M. Stoeckelhuber, K. Lauber, D. Scherfeld, et al.
Phosphatidylethanolamine critically supports internalization of cell-penetrating protein C inhibitor
J. Cell Biol., November 19, 2007; 179(4): 793 - 804.
[Abstract] [Full Text] [PDF]

I. C.A. Munnix, M. J.E. Kuijpers, J. Auger, C. M.L.G.D. Thomassen, P. Panizzi, M. A.M. van Zandvoort, J. Rosing, P. E. Bock, S. P. Watson, and J. W.M. Heemskerk
Segregation of Platelet Aggregatory and Procoagulant Microdomains in Thrombus Formation: Regulation by Transient Integrin Activation
Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2484 - 2490.
[Abstract] [Full Text] [PDF]

M. Bonomini, V. Sirolli, S. Dottori, L. Amoroso, L. Di Liberato, and A. Arduini
L-carnitine inhibits a subset of platelet activation responses in chronic uraemia
Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2623 - 2629.
[Abstract] [Full Text] [PDF]

Y. Wang, W. Beck, R. Deppisch, S. M. Marshall, N. A. Hoenich, and M. G. Thompson
Advanced glycation end products elicit externalization of phosphatidylserine in a subpopulation of platelets via 5-HT2A/2C receptors
Am J Physiol Cell Physiol, July 1, 2007; 293(1): C328 - C336.
[Abstract] [Full Text] [PDF]

A. Tesse, F. Meziani, E. David, N. Carusio, H. Kremer, F. Schneider, and R. Andriantsitohaina
Microparticles from preeclamptic women induce vascular hyporeactivity in vessels from pregnant mice through an overproduction of NO
Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H520 - H525.
[Abstract] [Full Text] [PDF]

G. Boden, V. Vaidyula, C. Homko, M. Mozzoli, and A. K. Rao
Differential effects of somatostatin on circulating tissue factor procoagulant activity and protein
Am J Physiol Endocrinol Metab, May 1, 2007; 292(5): E1333 - E1339.
[Abstract] [Full Text] [PDF]

J. G. Ledford, M. Kovarova, and B. H. Koller
Impaired Host Defense in Mice Lacking ONZIN
J. Immunol., April 15, 2007; 178(8): 5132 - 5143.
[Abstract] [Full Text] [PDF]

S.-M. Chung, O.-N. Bae, K.-M. Lim, J.-Y. Noh, M.-Y. Lee, Y.-S. Jung, and J.-H. Chung
Lysophosphatidic Acid Induces Thrombogenic Activity Through Phosphatidylserine Exposure and Procoagulant Microvesicle Generation in Human Erythrocytes
Arterioscler Thromb Vasc Biol, February 1, 2007; 27(2): 414 - 421.
[Abstract] [Full Text] [PDF]

M.-L. Liu, M. P. Reilly, P. Casasanto, S. E. McKenzie, and K. J. Williams
Cholesterol Enrichment of Human Monocyte/Macrophages Induces Surface Exposure of Phosphatidylserine and the Release of Biologically-Active Tissue Factor-Positive Microvesicles
Arterioscler Thromb Vasc Biol, February 1, 2007; 27(2): 430 - 435.
[Abstract] [Full Text] [PDF]

F. A. Kuypers
Membrane Lipid Alterations in Hemoglobinopathies
Hematology, January 1, 2007; 2007(1): 68 - 73.
[Abstract] [Full Text] [PDF]

K. I. Ataga and N. S. Key
Hypercoagulability in Sickle Cell Disease: New Approaches to an Old Problem
Hematology, January 1, 2007; 2007(1): 91 - 96.
[Abstract] [Full Text] [PDF]

M. C. Martinez, F. Larbret, F. Zobairi, J. Coulombe, N. Debili, W. Vainchenker, M. Ruat, and J.-M. Freyssinet
Transfer of differentiation signal by membrane microvesicles harboring hedgehog morphogens
Blood, November 1, 2006; 108(9): 3012 - 3020.
[Abstract] [Full Text] [PDF]

F. Meziani, A. Tesse, E. David, M. C. Martinez, R. Wangesteen, F. Schneider, and R. Andriantsitohaina
Shed Membrane Particles from Preeclamptic Women Generate Vascular Wall Inflammation and Blunt Vascular Contractility
Am. J. Pathol., October 1, 2006; 169(4): 1473 - 1483.
[Abstract] [Full Text] [PDF]

T. A. Whale, H. L. Wilson, S. K. Tikoo, L. A. Babiuk, and P. J. Griebel
Passively acquired membrane proteins alter the functional capacity of bovine polymorphonuclear cells
J. Leukoc. Biol., September 1, 2006; 80(3): 481 - 491.
[Abstract] [Full Text] [PDF]

J. I. Elliott, A. Sardini, J. C. Cooper, D. R. Alexander, S. Davanture, G. Chimini, and C. F. Higgins
Phosphatidylserine exposure in B lymphocytes: a role for lipid packing
Blood, September 1, 2006; 108(5): 1611 - 1617.
[Abstract] [Full Text] [PDF]

C. M. Boulanger, N. Amabile, and A. Tedgui
Circulating Microparticles: A Potential Prognostic Marker for Atherosclerotic Vascular Disease
Hypertension, August 1, 2006; 48(2): 180 - 186.
[Full Text] [PDF]

N. Papo, D. Seger, A. Makovitzki, V. Kalchenko, Z. Eshhar, H. Degani, and Y. Shai
Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic Peptide.
Cancer Res., May 15, 2006; 66(10): 5371 - 5378.
[Abstract] [Full Text] [PDF]

J.-J. Stampfuss, P. Censarek, J. W. Fischer, K. Schror, and A.-A. Weber
Rapid Release of Active Tissue Factor From Human Arterial Smooth Muscle Cells Under Flow Conditions
Arterioscler Thromb Vasc Biol, May 1, 2006; 26(5): e34 - e37.
[Abstract] [Full Text] [PDF]

Y. Lampl, M. Lorberboym, F. G. Blankenberg, M. Sadeh, and R. Gilad
Annexin V SPECT imaging of phosphatidylserine expression in patients with dementia
Neurology, April 25, 2006; 66(8): 1253 - 1254.
[Abstract] [Full Text] [PDF]

R. R. Bach
Tissue Factor Encryption
Arterioscler Thromb Vasc Biol, March 1, 2006; 26(3): 456 - 461.
[Abstract] [Full Text] [PDF]

N. A. Neidlinger, S. K. Larkin, A. Bhagat, G. P. Victorino, and F. A. Kuypers
Hydrolysis of Phosphatidylserine-exposing Red Blood Cells by Secretory Phospholipase A2 Generates Lysophosphatidic Acid and Results in Vascular Dysfunction
J. Biol. Chem., January 13, 2006; 281(2): 775 - 781.
[Abstract] [Full Text] [PDF]

H. H. Boersma, B. L.J.H. Kietselaer, L. M.L. Stolk, A. Bennaghmouch, L. Hofstra, J. Narula, G. A.K. Heidendal, and C. P.M. Reutelingsperger
Past, Present, and Future of Annexin A5: From Protein Discovery to Clinical Applications
J. Nucl. Med., December 1, 2005; 46(12): 2035 - 2050.
[Abstract] [Full Text] [PDF]

A. Tesse, M. C. Martinez, B. Hugel, K. Chalupsky, C. D. Muller, F. Meziani, D. Mitolo-Chieppa, J.-M. Freyssinet, and R. Andriantsitohaina
Upregulation of Proinflammatory Proteins Through NF-{kappa}B Pathway by Shed Membrane Microparticles Results in Vascular Hyporeactivity
Arterioscler Thromb Vasc Biol, December 1, 2005; 25(12): 2522 - 2527.
[Abstract] [Full Text] [PDF]

I. C.A. Munnix, A. Strehl, M. J.E. Kuijpers, J. M. Auger, P. E.J. van der Meijden, M. A.M. van Zandvoort, M. G.A. oude Egbrink, B. Nieswandt, and J. W.M. Heemskerk
The Glycoprotein VI-Phospholipase C{gamma}2 Signaling Pathway Controls Thrombus Formation Induced by Collagen and Tissue Factor In Vitro and In Vivo
Arterioscler Thromb Vasc Biol, December 1, 2005; 25(12): 2673 - 2678.
[Abstract] [Full Text] [PDF]

A. Kurz, D. Viertel, A. Herrmann, and K. Muller
Localization of phosphatidylserine in boar sperm cell membranes during capacitation and acrosome reaction
Reproduction, November 1, 2005; 130(5): 615 - 626.
[Abstract] [Full Text] [PDF]

D. C. McMillan, C. L. Powell, Z. S. Bowman, J. D. Morrow, and D. J. Jollow
Lipids versus Proteins as Major Targets of Pro-Oxidant, Direct-Acting Hemolytic Agents
Toxicol. Sci., November 1, 2005; 88(1): 274 - 283.
[Abstract] [Full Text] [PDF]

D. A. Coil and A. D. Miller
Enhancement of Enveloped Virus Entry by Phosphatidylserine
J. Virol., September 1, 2005; 79(17): 11496 - 11500.
[Abstract] [Full Text] [PDF]

Z. S. Bowman, J. D. Morrow, D. J. Jollow, and D. C. McMillan
Primaquine-Induced Hemolytic Anemia: Role of Membrane Lipid Peroxidation and Cytoskeletal Protein Alterations in the Hemotoxicity of 5-Hydroxyprimaquine
J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 838 - 845.
[Abstract] [Full Text] [PDF]

C. M. Boulanger and A. Tedgui
Dying for attention: Microparticles and angiogenesis
Cardiovasc Res, July 1, 2005; 67(1): 1 - 3.
[Full Text] [PDF]

J. F.W. Keuren, S. J.H. Wielders, H. Ulrichts, T. Hackeng, J. W.M. Heemskerk, H. Deckmyn, E. M. Bevers, and T. Lindhout
Synergistic Effect of Thrombin on Collagen-Induced Platelet Procoagulant Activity Is Mediated Through Protease-Activated Receptor-1
Arterioscler Thromb Vasc Biol, July 1, 2005; 25(7): 1499 - 1505.
[Abstract] [Full Text] [PDF]

X. Huang, M. Bennett, and P. E. Thorpe
A Monoclonal Antibody that Binds Anionic Phospholipids on Tumor Blood Vessels Enhances the Antitumor Effect of Docetaxel on Human Breast Tumors in Mice
Cancer Res., May 15, 2005; 65(10): 4408 - 4416.
[Abstract] [Full Text] [PDF]

H.-H. Chen, C. P. Vicente, L. He, D. M. Tollefsen, and T.-C. Wun
Fusion proteins comprising annexin V and Kunitz protease inhibitors are highly potent thrombogenic site-directed anticoagulants
Blood, May 15, 2005; 105(10): 3902 - 3909.
[Abstract] [Full Text] [PDF]

Y. Nakai, Y. Nomura, T. Sato, A. Shiratsuchi, and Y. Nakanishi
Isolation of a Drosophila Gene Coding for a Protein Containing a Novel Phosphatidylserine-Binding Motif
J. Biochem., May 1, 2005; 137(5): 593 - 599.
[Abstract] [Full Text] [PDF]

M. C. Martinez, A. Tesse, F. Zobairi, and R. Andriantsitohaina
Shed membrane microparticles from circulating and vascular cells in regulating vascular function
Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1004 - H1009.
[Abstract] [Full Text] [PDF]

J. H. W. Distler, A. Jungel, L. C. Huber, C. A. Seemayer, C. F. Reich III, R. E. Gay, B. A. Michel, A. Fontana, S. Gay, D. S. Pisetsky, et al.
The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles
PNAS, February 22, 2005; 102(8): 2892 - 2897.
[Abstract] [Full Text] [PDF]

S. Ran, J. He, X. Huang, M. Soares, D. Scothorn, and P. E. Thorpe
Antitumor Effects of a Monoclonal Antibody that Binds Anionic Phospholipids on the Surface of Tumor Blood Vessels in Mice
Clin. Cancer Res., February 15, 2005; 11(4): 1551 - 1562.
[Abstract] [Full Text] [PDF]

M. Bonomini, V. Sirolli, G. Merciaro, T. Antidormi, L. Di Liberato, U. Brummer, M. Papponetti, P. Cappelli, P. Di Gregorio, and A. Arduini
Red blood cells may contribute to hypercoagulability in uraemia via enhanced surface exposure of phosphatidylserine
Nephrol. Dial. Transplant., February 1, 2005; 20(2): 361 - 366.
[Abstract] [Full Text] [PDF]

Y. Wu, B. Lau, S. Smith, K. Troyan, and D. E. Barnett Foster
Enteropathogenic Escherichia coli Infection Triggers Host Phospholipid Metabolism Perturbations
Infect. Immun., December 1, 2004; 72(12): 6764 - 6772.
[Abstract] [Full Text] [PDF]

B. O. Jensen, F. Selheim, S. O. Doskeland, A. R. L. Gear, and H. Holmsen
Protein kinase A mediates inhibition of the thrombin-induced platelet shape change by nitric oxide
Blood, November 1, 2004; 104(9): 2775 - 2782.
[Abstract] [Full Text] [PDF]

X. Wang, N. Li, B. Liu, H. Sun, T. Chen, H. Li, J. Qiu, L. Zhang, T. Wan, and X. Cao
A Novel Human Phosphatidylethanolamine-binding Protein Resists Tumor Necrosis Factor {alpha}-induced Apoptosis by Inhibiting Mitogen-activated Protein Kinase Pathway Activation and Phosphatidylethanolamine Externalization
J. Biol. Chem., October 29, 2004; 279(44): 45855 - 45864.
[Abstract] [Full Text] [PDF]

D. A. Coil and A. D. Miller
Phosphatidylserine Is Not the Cell Surface Receptor for Vesicular Stomatitis Virus
J. Virol., October 15, 2004; 78(20): 10920 - 10926.
[Abstract] [Full Text] [PDF]

B. Varadi, K. Kolev, K. Tenekedjiev, G. Meszaros, I. Kovalszky, C. Longstaff, and R. Machovich
Phospholipid Barrier to Fibrinolysis: ROLE FOR THE ANIONIC POLAR HEAD CHARGE AND THE GEL PHASE CRYSTALLINE STRUCTURE
J. Biol. Chem., September 17, 2004; 279(38): 39863 - 39871.
[Abstract] [Full Text] [PDF]

X. Chen, K. Doffek, S. L. Sugg, and J. Shilyansky
Phosphatidylserine Regulates the Maturation of Human Dendritic Cells
J. Immunol., September 1, 2004; 173(5): 2985 - 2994.
[Abstract] [Full Text] [PDF]

O. Aras, A. Shet, R. R. Bach, J. L. Hysjulien, A. Slungaard, R. P. Hebbel, G. Escolar, B. Jilma, and N. S. Key
Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia
Blood, June 15, 2004; 103(12): 4545 - 4553.
[Abstract] [Full Text] [PDF]

M.-P. Courageot, S. Lepine, M. Hours, F. Giraud, and J.-C. Sulpice
Involvement of Sodium in Early Phosphatidylserine Exposure and Phospholipid Scrambling Induced by P2X7 Purinoceptor Activation in Thymocytes
J. Biol. Chem., May 21, 2004; 279(21): 21815 - 21823.
[Abstract] [Full Text] [PDF]

S. V. Brodsky, F. Zhang, A. Nasjletti, and M. S. Goligorsky
Endothelium-derived microparticles impair endothelial function in vitro
Am J Physiol Heart Circ Physiol, May 1, 2004; 286(5): H1910 - H1915.
[Abstract] [Full Text] [PDF]

S. C. Frasch, P. M. Henson, K. Nagaosa, M. B. Fessler, N. Borregaard, and D. L. Bratton
Phospholipid Flip-Flop and Phospholipid Scramblase 1 (PLSCR1) Co-localize to Uropod Rafts in Formylated Met-Leu-Phe-stimulated Neutrophils
J. Biol. Chem., April 23, 2004; 279(17): 17625 - 17633.
[Abstract] [Full Text] [PDF]

S. Martin, A. Tesse, B. Hugel, M. C. Martinez, O. Morel, J.-M. Freyssinet, and R. Andriantsitohaina
Shed Membrane Particles From T Lymphocytes Impair Endothelial Function and Regulate Endothelial Protein Expression
Circulation, April 6, 2004; 109(13): 1653 - 1659.
[Abstract] [Full Text] [PDF]

M. Bonomini, E. Ballone, S. Di Stante, T. Bucciarelli, S. Dottori, A. Arduini, A. Urbani, and V. Sirolli
Removal of uraemic plasma factor(s) using different dialysis modalities reduces phosphatidylserine exposure in red blood cells
Nephrol. Dial. Transplant., January 1, 2004; 19(1): 68 - 74.
[Abstract] [Full Text] [PDF]

K. Kurosaka, M. Takahashi, N. Watanabe, and Y. Kobayashi
Silent Cleanup of Very Early Apoptotic Cells by Macrophages
J. Immunol., November 1, 2003; 171(9): 4672 - 4679.
[Abstract] [Full Text] [PDF]

M. Dias-Baruffi, H. Zhu, M. Cho, S. Karmakar, R. P. McEver, and R. D. Cummings
Dimeric Galectin-1 Induces Surface Exposure of Phosphatidylserine and Phagocytic Recognition of Leukocytes without Inducing Apoptosis
J. Biol. Chem., October 17, 2003; 278(42): 41282 - 41293.
[Abstract] [Full Text] [PDF]

A. S. Shet, O. Aras, K. Gupta, M. J. Hass, D. J. Rausch, N. Saba, L. Koopmeiners, N. S. Key, and R. P. Hebbel
Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes
Blood, October 1, 2003; 102(7): 2678 - 2683.
[Abstract] [Full Text] [PDF]

M. J. VanWijk, E. VanBavel, A. Sturk, and R. Nieuwland
Microparticles in cardiovascular diseases
Cardiovasc Res, August 1, 2003; 59(2): 277 - 287.
[Abstract] [Full Text] [PDF]

V. E. Kagan, G. G. Borisenko, B. F. Serinkan, Y. Y. Tyurina, V. A. Tyurin, J. Jiang, S. X. Liu, A. A. Shvedova, J. P. Fabisiak, W. Uthaisang, et al.
Appetizing rancidity of apoptotic cells for macrophages: oxidation, externalization, and recognition of phosphatidylserine
Am J Physiol Lung Cell Mol Physiol, July 1, 2003; 285(1): L1 - L17.
[Abstract] [Full Text] [PDF]

P. A. Verhoef, M. Estacion, W. Schilling, and G. R. Dubyak
P2X7 Receptor-Dependent Blebbing and the Activation of Rho-Effector Kinases, Caspases, and IL-1{beta} Release
J. Immunol., June 1, 2003; 170(11): 5728 - 5738.
[Abstract] [Full Text] [PDF]

P. G. Gallagher, S. H. Chang, M. P. Rettig, J. E. Neely, C. A. Hillery, B. D. Smith, and P. S. Low
Altered erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis
Blood, June 1, 2003; 101(11): 4625 - 4627.
[Abstract] [Full Text] [PDF]

N. Papo, M. Shahar, L. Eisenbach, and Y. Shai
A Novel Lytic Peptide Composed of DL-Amino Acids Selectively Kills Cancer Cells in Culture and in Mice
J. Biol. Chem., May 30, 2003; 278(23): 21018 - 21023.
[Abstract] [Full Text] [PDF]

A. Yu, C. R. McMaster, D. M. Byers, N. D. Ridgway, and H. W. Cook
Stimulation of Phosphatidylserine Biosynthesis and Facilitation of UV-induced Apoptosis in Chinese Hamster Ovary Cells Overexpressing Phospholipid Scramblase 1
J. Biol. Chem., March 7, 2003; 278(11): 9706 - 9714.
[Abstract] [Full Text] [PDF]

J. Narula and H. W. Strauss
P.S. I Love You: Implications of Phosphatidyl Serine (PS) Reversal in Acute Ischemic Syndromes
J. Nucl. Med., March 1, 2003; 44(3): 397 - 399.
[Full Text] [PDF]

D. L. Daleke
Regulation of transbilayer plasma membrane phospholipid asymmetry
J. Lipid Res., February 1, 2003; 44(2): 233 - 242.
[Abstract] [Full Text] [PDF]

S. Ran, A. Downes, and P. E. Thorpe
Increased Exposure of Anionic Phospholipids on the Surface of Tumor Blood Vessels
Cancer Res., November 1, 2002; 62(21): 6132 - 6140.
[Abstract] [Full Text] [PDF]

S. V. Brodsky, K. Malinowski, M. Golightly, J. Jesty, and M. S. Goligorsky
Plasminogen Activator Inhibitor-1 Promotes Formation of Endothelial Microparticles With Procoagulant Potential
Circulation, October 29, 2002; 106(18): 2372 - 2378.
[Abstract] [Full Text] [PDF]

K. Ayi, G. Giribaldi, A. Skorokhod, E. Schwarzer, P. T. Prendergast, and P. Arese
16{alpha}-Bromoepiandrosterone, an Antimalarial Analogue of the Hormone Dehydroepiandrosterone, Enhances Phagocytosis of Ring Stage Parasitized Erythrocytes: a Novel Mechanism for Antimalarial Activity
Antimicrob. Agents Chemother., October 1, 2002; 46(10): 3180 - 3184.
[Abstract] [Full Text] [PDF]

L. J. C. Bolchoz, J. D. Morrow, D. J. Jollow, and D. C. McMillan
Primaquine-Induced Hemolytic Anemia: Effect of 6-Methoxy-8-hydroxylaminoquinoline on Rat Erythrocyte Sulfhydryl Status, Membrane Lipids, Cytoskeletal Proteins, and Morphology
J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 141 - 148.
[Abstract] [Full Text] [PDF]

A. M. Post, P. D. Katsikis, J. F. Tait, S. M. Geaghan, H. W. Strauss, and F. G. Blankenberg
Imaging Cell Death with Radiolabeled Annexin V in an Experimental Model of Rheumatoid Arthritis
J. Nucl. Med., October 1, 2002; 43(10): 1359 - 1365.
[Abstract] [Full Text] [PDF]

L. Leo, J. Di Paola, B. A. Judd, G. A. Koretzky, and S. R. Lentz
Role of the adapter protein SLP-76 in GPVI-dependent platelet procoagulant responses to collagen
Blood, September 26, 2002; 100(8): 2839 - 2844.
[Abstract] [Full Text] [PDF]

T. Belhocine, N. Steinmetz, R. Hustinx, P. Bartsch, G. Jerusalem, L. Seidel, P. Rigo, and A. Green
Increased Uptake of the Apoptosis-imaging Agent 99mTc Recombinant Human Annexin V in Human Tumors after One Course of Chemotherapy as a Predictor of Tumor Response and Patient Prognosis
Clin. Cancer Res., September 1, 2002; 8(9): 2766 - 2774.
[Abstract] [Full Text] [PDF]

C. Kunzelmann-Marche, J.-M. Freyssinet, and M. C. Martinez
Loss of Plasma Membrane Phospholipid Asymmetry Requires Raft Integrity. ROLE OF TRANSIENT RECEPTOR POTENTIAL CHANNELS AND ERK PATHWAY
J. Biol. Chem., May 24, 2002; 277(22): 19876 - 19881.
[Abstract] [Full Text] [PDF]

F. Sabatier, V. Roux, F. Anfosso, L. Camoin, J. Sampol, and F. Dignat-George
Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity
Blood, May 13, 2002; 99(11): 3962 - 3970.
[Abstract] [Full Text] [PDF]

J. Valles, M. T. Santos, J. Aznar, M. Martinez, A. Moscardo, M. Pinon, M. J. Broekman, and A. J. Marcus
Platelet-erythrocyte interactions enhance alpha IIbbeta 3 integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo
Blood, May 13, 2002; 99(11): 3978 - 3984.
[Abstract] [Full Text] [PDF]

L.J de Windt, K Cox, L Hofstra, and P.A Doevendans
Molecular and genetic aspects of cardiac fatty acid homeostasis in health and disease
Eur. Heart J., May 2, 2002; 23(10): 774 - 787.
[Full Text] [PDF]

M. B. Brooks, J. L. Catalfamo, H. A. Brown, P. Ivanova, and J. Lovaglio
A hereditary bleeding disorder of dogs caused by a lack of platelet procoagulant activity
Blood, April 1, 2002; 99(7): 2434 - 2441.
[Abstract] [Full Text] [PDF]

U. Salzer, P. Hinterdorfer, U. Hunger, C. Borken, and R. Prohaska
Ca++-dependent vesicle release from erythrocytes involves stomatin-specific lipid rafts, synexin (annexin VII), and sorcin
Blood, April 1, 2002; 99(7): 2569 - 2577.
[Abstract] [Full Text] [PDF]

H.-J. M. Brinkman, K. Mertens, and J. A. van Mourik
Phospholipid-Binding Domain of Factor VIII Is Involved in Endothelial Cell-Mediated Activation of Factor X by Factor IXa
Arterioscler Thromb Vasc Biol, March 1, 2002; 22(3): 511 - 516.
[Abstract] [Full Text] [PDF]

B. N. Y. Setty, S. Kulkarni, and M. J. Stuart
Role of erythrocyte phosphatidylserine in sickle red cell-endothelial adhesion
Blood, March 1, 2002; 99(5): 1564 - 1571.
[Abstract] [Full Text] [PDF]

P. K. Hanson, A. M. Grant, and J. W. Nichols
NBD-labeled phosphatidylcholine enters the yeast vacuole via the pre-vacuolar compartment
J. Cell Sci., January 7, 2002; 115(13): 2725 - 2733.
[Abstract] [Full Text] [PDF]

K. Presseizen, Z. Friedman, H. Shapiro, J. Radnay, and M. H. Ellis
Phosphatidylserine Expression on the Platelet Membrane of Patients with Myeloproliferative Disorders and its Effect on Platelet-Dependent Thrombin Formation
Clinical and Applied Thrombosis/Hemostasis, January 1, 2002; 8(1): 33 - 39.
[Abstract] [PDF]

J. Huber, A. Vales, G. Mitulovic, M. Blumer, R. Schmid, J. L. Witztum, B. R. Binder, and N. Leitinger
Oxidized Membrane Vesicles and Blebs From Apoptotic Cells Contain Biologically Active Oxidized Phospholipids That Induce Monocyte-Endothelial Interactions
Arterioscler Thromb Vasc Biol, January 1, 2002; 22(1): 101 - 107.
[Abstract] [Full Text] [PDF]

This Article

Full Text (PDF)

Alert me when this article is cited

Alert me if a correction is posted

Citation Map

Services

Email this article to a friend

Similar articles in this journal

Similar articles in PubMed

Alert me to new issues of the journal

Download to citation manager

Rights and Permissions

Citing Articles

Citing Articles via HighWire

Citing Articles via CrossRef

Citing Articles via Google Scholar

Google Scholar

Articles by Zwaal, R. F.A.

Articles by Schroit, A. J.

Search for Related Content

PubMed

PubMed Citation

Articles by Zwaal, R. F.A.

Articles by Schroit, A. J.

Related Collections

Review Articles

Social Bookmarking


What's this?

  Copyright © 1997 by American Society of Hematology         Online ISSN: 1528-0020





	Copyright © 1997 by American Society of Hematology Online ISSN: 1528-0020

Blood, Vol. 89 No. 4 (February 15), 1997: pp. 1121-1132

Pathophysiologic Implications of Membrane Phospholipid Asymmetry in Blood Cells

© 1997 by The American Society of Hematology.